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PREFACE 
 
 
Radiopharmaceuticals are used in the field of nuclear medicine as 
radioactive tracers in medical imaging and in therapy for many diseases. 
Common isotopes that are used in nuclear imaging include: fluorine-18, 
gallium-67, krypton-81m, rubidium-82, nitrogen-13, technetium-99m, 
indium-111, iodine-123, xenon-133, and thallium-201. In a nuclear 
medicine diagnostic procedure, small amounts of radiopharmaceuticals 
are introduced into the body by injection, swallowing or inhalation. The 
amount of the radiopharmaceutical that is used is chosen to provide the 
lowest radiation exposure to a patient while ensuring an accurate medical 
evaluation. A radioisotope used for diagnosis must emit gamma rays of 
sufficient energy to escape from the body and it must have a half-life 
short enough for it to decay away soon after imaging is completed. The 
radioisotope most widely used in medicine is technetium-99m, employed 
in some 80% of all nuclear medicine procedures. We have great pleasure 
in presenting this book which is very comprehensive and dependable for 
various nuclear medicine study. Every topic has been explained 
intensively to suit the needs of readers. 
 
 
 
 
Siti Amira Othman 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1 
 
Applications of Radiopharmaceutical in Nuclear Medicine
   ISBN 978-967-2306-01-6
2019 
 
CHAPTER 1 
 
SAMARIUM-153 
 
Nuralisha Qamarul Baharuddin 
 
 
 
1.0 INTRODUCTION 
 
Samarium is a chemical element with symbol Sm and atomic number 62. 
It is a moderately hard silvery metal that slowly oxidizes in air. Being a 
typical member of the lanthanide series, samarium usually assumes the 
oxidation state +3. Samarium was discovered in 1879 by the French 
chemist Paul-Mile Lecoq de Boisbaudran and named after the mineral 
samarskite from which it was isolated. The mineral itself was earlier 
named after a Russian mine official, Colonel Vassili Samarsky- 
Bykhovets, who thereby became the first person to have a chemical 
element named after him, albeit indirectly. Although classified as a rare-
earth element, samarium is the 40th most abundant element in the Earth's 
crust and is more common than such metals as tin. Samarium have a 
radioactive isotope known as samarium-153 (Sm) the active component 
of the drug samarium (153Sm) lexidronam (Quadramet), which kills 
cancer cells in the treatment of lung cancer, prostate cancer, breast cancer 
and osteosarcoma. Another isotope, samarium-149, is a strong neutron 
absorber and is therefore added to the control rods of nuclear reactors. It 
is also formed as a decay product during the reactor operation and is one 
of the important factors considered in the reactor design and operation. 
Other applications of samarium include catalysis of chemical reactions, 
radioactive dating and an X-ray laser. 
 
Samarium-153 Lexidronam is a radiopharmaceutical which one of 
radioactive substance used to treat bone cancer and other cancer that have 
spread to the bone. Samarium-153 Lexidronam is a radioactive form of 
the element samarium and a therapeutic agent which consist of 
radioactive samarium and a tetra phosphonate chelator, ethylenediamine 
tetra (methylene phosphonic acid) (EDTMP). It collects in bone, where 
it releases radiation that may kill cancer cells. Samarium- 153 
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Lexidronam which is very effective in relieving the pain of secondary 
cancers present in the bone, sold as Quadramet. Also very effective for 
prostate and breast cancer. Quadramet (samarium- 153 lexidronam) is 
formulated as a sterile, non-pyrogenic, clear, and colorless to light amber 
isotonic solution of samarium-153 lexidronam for intravenous 
administration. Quadramet (samarium - 153 lexidronam) does not 
contain a preservative.  
 
Samarium-153 is produced in high yield and purity by neutron irradiation 
of isotopically enriched samarium-152 oxide. It emits both medium-
energy beta particles and a gamma photon, and has a physical half-life of 
46.3 hours (1.93 days). Samarium-153 has average and maximum beta 
particle ranges in water of 0.5 mm and 3.0 mm, respectively. For external 
radiation, the specific gamma-ray constant for samarium-153 is 0.46 
R/mCi-hr at 1 cm (1.24x10-5 mSv/MBq- hr at 1 Meter). The half-value 
thickness of lead (Pb) for samarium-153 is approximately 0.10 mm. The 
use of 1 mm of lead will decrease the external radiation exposure by a 
factor of approximately 1,000. Quadramet (samarium-153 lexidronam) 
should be stored in a lead-shielded container and frozen until use. 
 
 
1.1 APPLICATIONS 
 
The treating clinician must advise the patient on reducing unnecessary 
radiation exposure to family members and the public. Following 
treatment, patients should thoroughly avoid pregnancy for at least 6 
months after 153Sm-lexidronam and 186Re-etidronate, and even longer for 
89Sr. In reality, it is unlikely that women of childbearing age will be 
eligible for this therapy. Patients should be appropriately hydrated before 
and after therapy. If the treatment is performed on an out-patient basis, 
patients should remain in the nuclear medicine facility for the first 4–6 h 
after administration.  For 153Sm-lexidronam, it is nearly completed after 
the first 8–12 h after administration. Patients should be advised to 
observe rigorous hygiene to avoid contaminating groups at risk using the 
same toilet facility. Patients should be warned to avoid soiling 
underclothing or areas around toilet bowls for 1week post-injection and 
that significantly soiled clothing should be washed separately. A double 
toilet flush is recommended after urination. Patients should wash their 
hands after urination.  If contaminated with urine, patients should wash 
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their hands abundantly with cold water without scrubbing. Because 
urinary excretion of 153Sm-lexidronam is fast and takes place 
predominantly during the first 8–12 h after injection, special caution for 
urinary contamination should be taken during this first period.  
 
Incontinent patients should be catheterized before radiopharmaceutical 
administration for radioprotection of relatives and/or caring personnel. 
The catheter should remain in place for an appropriate period of time 
(89Sr = 4 days, 186Reetidronate= 2–3 days, 153Sm-lexidronam=24 h). 
Catheter bags should be emptied frequently. Gloves should be worn by 
staff caring for catheterized patients. If in-patient treatment is required, 
nursing personnel must be instructed in radiation safety. Any significant 
medical conditions should be noted and contingency plans made in case 
radiation precautions must be breached for a medical emergency. 
Concern about radiation exposure should not interfere with the prompt 
appropriate medical treatment of the patient. Haematological toxicity is 
the main side effect of bone seeking radiopharmaceuticals. Therefore, 
periodical haematological monitoring may be useful up to 6 weeks post-
therapy (153Sm-lexidronam, 186Re-etidronate) to exclude significant 
myelosuppression in high-risk patients. After treatment with 89Sr, longer 
follow-up is necessary because of prolonged myelosuppressive toxicity 
(12–16 weeks). Post-therapy scintigraphy, when feasible, may be of 
value to check tumour extent and radiopharmaceutical distribution and 
to perform dosimetry calculations. 
  
The radioactive samarium is taken up in the bone cancer area and gives 
off radiation that helps provide relief of pain. Samarium (Sm-153) 
lexidronam is to be given only by or under the direct supervision of a 
doctor with specialized training in nuclear medicine or radiation 
oncology. This product is available in the injectable or in solution dosage 
forms. The treatment of a cancer patient demands a different approach 
than the diagnostic mentality we are used to in nuclear medicine. The 
patient must be evaluated as a whole. Patients may have multiple organ 
systems involved by tumor and are likely to have concomitant diseases 
because of the age range of the patients.  Each patient must be evaluated 
individually. Management of pain in the cancer patient is often poorly 
handled. Since the nuclear physician will often be seeing a patient who 
has little or no soft-tissue involvement, we believe an aggressive 
approach to the handling of their skeletal pain is in order. These are not 
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easy patients to treat, but they are, as a group, among the most 
cooperative you will see because of their concern. They are also among 
the most grateful patients you will have, as they appreciate any relief 
from the continuous, toothache type of pain they must endure. Systemic 
radio isotopic therapy utilizes the basic tracer principles of nuclear 
medicine. The mechanisms of uptake of labeled phosphonates and 
elemental strontium are well known to nuclear physicians. Systemic 
radio isotopic therapy holds great promise for the near future. We should 
soon have available one or more bone-seeking therapeutic 
pharmaceuticals, including 89Sr-chloride, and one or more of the labeled 
phosphornates. The nuclear physician needs to be aware of these 
developments, and incorporate bone-seeking radio pharmaceuticals into 
his or her practice as soon as they become available.  
 
 
1.2 CONCLUSION 
 
As conclusions, Sm-153 offers a safe and effective treatment option in 
patients. It is a systemic, simple and well-tolerated single-session 
procedure that usually achieves good pain palliation and sometimes pain-
free periods lasting several months. 
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CHAPTER 2 
 
PALLADIUM-103 
 
Noradilah Mohamad Saufi 
 
2.0 INTRODUCTION 
 
Palladium was a rare metallic element of the platinum group. Palladium-
103 was produced by absorption of neutron from palladium-102. It was 
decay through electron capture of the Pd-102. Chemical formula for 
palladium-103 is Pd-103 with atomic weight equal to 106.4, atomic 
number equal to 46 and the specific gravity was 12 at 20°C. The valence 
of Pd were 2, 3, or 4 and the relative density is 1202 with melting and 
boiling point were equal to 1555°C and 2964°C respectively. Average 
power source of Pd-103 is 0.021 MeV (equal to 21 keV) of X-Rays with 
half-life of 17.0 days. The decaying of 103Pd to 103Rh, which undergoes 
internal conversion and emits characteristic X-rays (range: 20-23 keV). 
Auger electrons also emitted. The properties of it were silver-white, 
ductile and malleable. It is from platinum metal group occurring 
principally in nickel-bearing ore that used as a hydrogenation catalyst 
and, was alloyed with gold, in jewelry. Palladium also harder and fusing 
more readily than platinum. It also used chiefly as a catalyst and in dental 
and other alloys.  However, Palladium also had been use in 
radiopharmaceutical treatment.   
 
Radiopharmaceuticals or radioactive pharmaceutical, was a nuclide or 
other chemical that used for diagnostic purposes or for radiation therapy. 
Pharmaceutical also    define as pharmaceutics preparation that labeled 
with a radionuclide in tracer or therapeutic concentration. Pd-103 also 
has been use medical treatment especially to detect the cancer. It clinical 
use was interstitial brachytherapy (prostate) and the clinical form is in 
seed model 200 (Theragenics Corp). The seed was 4.5 mm x 0.8 mm in 
size and two graphite pellets plated with Pd-103 in titanium tube. The 
identification on X-rays are allowed from the lead marker between the 
pellets. 
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As reported by Monroe and Williamson, the TheraSeed consists of two 
cylindrical graphite pellets coated with radioactive palladium and 
separated by a cylindrical lead marker. (Figure 4) The graphite cylinders 
have a diameter of 0.560 mm and length of 0.890 mm. The lead marker 
is 1.09 mm long and 0.500 mm in diameter. The thickness of Pd on the 
graphite is 2.20 mm. Encapsulation for the TheraSeed is a thin titanium 
tube that has an outer diameter of 0.826 mm with wall thickness of 
0.0560 mm. The ends are sealed with two titanium end cups that are 
0.040 mm thick. The end cups are composed of a 0.334 mm long hollow 
cylindrical section attached to a hemi-spherical shell. Both the cylindrical 
section and hemi-spherical shell have inner diameters of 0.306 mm. The 
overall source length is 4.500 mm and the active length is 4.23 mm 
calculated using the TG-43 effective line source length approximation. 
The maximum displacement of one of the cylindrical sources is 0.200 
mm along the seed axis and 0.075 mm in the radial direction.  
 
Dose rate constants calculated by dividing the dose to water per history 
in a (0.1 mm) 3 voxel centered on the reference position, (1 cm, Π/2), in 
the 30 x 30 x 30 cm3   of water phantom, by the air kerma strength per 
history (scored in vacuo). Dose rate constants are provided for air kerma 
strength calculated using voxels of 2.7 x 2.7 x 0.05 cm3 and 0.1 x 0.1 x 
0.05 cm3 of point that are located 10 cm from the source. The larger voxel 
size, averages the air kerma per history over a region covering roughly 
the same solid angle subtended by the primary collimator used for 
calibrating low-energy brachytherapy sources and is likely the most 
clinically relevant value. The small voxel serves to estimate the air kerma 
per history at a point on the transverse axis. 
 
2.1 APPLICATIONS 
 
The word ‘brachy’ is of Greek origin and means ‘close’ or ‘short-
distance.’ Prostate cancer brachytherapy literally means ‘therapy that is 
administered from a short distance away.’ This concept of treating 
prostate cancer through internal radiation therapy has been around since 
the early 20th century. 15 techniques were used involving the insertion 
of radiation into the prostate gland for first half of the 20th century. The 
success of these treatments was limited.  
 
 
 8 
 
Applications of Radiopharmaceutical in Nuclear Medicine
   ISBN 978-967-2306-01-6
2019 
In the 1960’s, the permanent insertion of radioactive material into the 
prostate gland was tried. Two doctors tried the interstitial insertion of 
gold-198 into the prostate gland. Another center used Iodine –125 seeds 
to irradiate the prostate through an incision. Unfortunately, the success 
of these techniques was poor due to the inability to see the prostate gland 
and the surrounding organs. Not until around 1980, when doctors began 
to use a transperineal needle template, transperineal needles, and the 
trans-rectal ultrasound, did brachytherapy become a viable prostate 
cancer treatment.   
 
Cells will not be damaged unless when they attempt to divide. Cancerous 
cells divide more quickly than healthy cells. Before undergoing mitosis, 
healthy cells are able to repair damage while cancerous cells are not. 
Unfortunately, if the dose is strong enough, healthy cells will be damaged 
to the point where they cannot repair themselves before division. 
Interstitial brachytherapy is able to deliver higher doses of radiation to 
an area concentrated within the prostate gland. 
 
The application of Pd-103 was used as seeds for Prostate Cancers. A 
study was done on ‘What patients should expect from Palladium-103 
brachytherapy or seed implantation for prostate cancer. As a treatment 
for prostate cancer, a radioactive Palladium-103 or Iodine-125 seeds are 
placed directly into the prostate gland. This treatment need a surgery to 
be done. It was proceed either after loading needles with a special "gun" 
or preloaded needles. Low-energy of X-Rays was give off to both of 
these seeds and majority of the radioactivity is released within a short 
period of time. A small volume of prostate tissue was irradiates by each 
of the seed. Because of that, a lots of seeds have to be placed throughout 
the prostate to cover the entire gland and the part of the cancer. Due to 
the release of low X-Ray radiation energy, radiation exposure to adjacent 
normal organs is reduced. 
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2.2 CONCLUSION 
 
Palladium was a rare metallic element of the platinum group. Palladium-
103 was produced by absorption of neutron from palladium-102. It was 
decay through electron capture of the Pd-102. Radiation was used in the 
treatment of prostate cancer because exposure to radiation damages the 
DNA of cells. There were two types of prostate cancer radiation 
treatments which are external and internal. It also called as interstitial. 
Brachytherapy was interstitial which was meaning that the treatment is 
administered from “within the tissue.” During the treatment, a bi-planer 
ultrasound probe was placed in the rectum to image the prostate. Along 
with fluoroscopy, the bi-planer ultrasound gives a multidimensional view 
of the prostate on several TV screens. Cystoscopy can also be used to 
treat underlying bladder conditions. Tiny surgical tools were passes 
through the scope to remove small bladder tumors and stones or to taking 
sample of bladder tissue. TheraSeed consists of two cylindrical graphite 
pellets coated with radioactive palladium and separated by a cylindrical 
lead marker. (Figure 4) The graphite cylinders have a diameter of 0.560 
mm and length of 0.890 mm. 
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CHAPTER 3 
 
 LUTETIUM-177 
 
Ain Nurhanna Zulhazmi 
 
3.0 INTRODUCTION 
 
With a symbol of Lu and atomic number 71, the chemical element is 
known as Lutetium. It also can withstand corrosion in dry air but not in 
moist air. Basically, this radioactive isotope is unstable. It will become 
more stable by two ways which are radioactive decay and emission of 
different types of radiation. Its half-life and atomic weight is 6.73 days 
and 174.967, respectively. Lutetium-177 is naturally consisting of one 
stable isotope 175Lu and one radioisotope that have long lifespan which 
is 176Lu.  175Lu exist about 97.41% in the earth, meanwhile 176Lu have 
2.59% in the earth with a half-life of 3.78 x 1010 years. However, its 
existence was never found as a free element in this earth. Normally 
Lutetium-177 was discovered through the ores which contains small 
amounts of all types of rare earth metals. In addition, Lutetium-177 can 
be used in many ways such as determine the age of minerals and 
meteorites, act as a catalyst in a chemical reaction and for radionuclide 
therapy on tumors. 
 
Although this element is very rare in the earth, it still has many functions. 
First, cracking hydrocarbons in the petrochemical industry can be done 
when lutetium oxide is used as a catalyst. Next, due to its long half-life, 
this element can be used in cancer therapy. The age of the meteorites can 
be discovered by using 176Lu too. The emitted radiation is used for cancer 
therapy by focusing the radiation emitted to the cancer area. The cancer 
area can be visualized by using nuclear medicine. The radiotherapist will 
target diagnostic radiopharmaceuticals and then, they will visualize the 
cancer area by using an imaging technique. Next, the cancer area will be 
treated with therapeutic radioactive molecules which capable of killing 
the cancer cells. The combination of those three therapies is known as 
theranostics. This targeted therapy is done by using Lutetium-177.  
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The targeted therapy includes the chemical attachment of stable 
Lutetium-177 to the cancer area after injection. During decay of 
Lutetium-177, it will emit low energy gamma photons. The low energy 
gamma photons will travel across the tissue and used for targeting 
visualization by external imaging. The cancer area will absorb energy 
from the emission of beta particle. Then, the energy will kill the cancer 
cells even though it travels in short distance in the tissue. Furthermore, 
neuroendocrine tumors occur when neoplasms arise from the cells of 
endocrine and nervous system. This disease can be treated by using 
Lutetium-177.   
 
Prostate-Specific Membrane Antigen Therapy or known as Lutetium-
177 PSMA Therapy is one of the treatment for cancer patient. This 
treatment normally used by people with an advance prostate cancer. It 
will prevent tumor from expand to unaffected area and decrease the size 
of the tumor. Furthermore, the treatment will help the doctors or surgeons 
to detect the symptoms for people to get this tumor. This treatment is 
used when the previous treatment or therapies have unsuccessful. 
 
3.1 APPLICATIONS 
 
The PSMA radionuclide therapy using Lutetium-177 is used to treat men 
with a prostate cancer. The surface of prostate cancer cells receptor is 
known as prostate-specific membrane antigen (PSMA). New small 
molecules peptides with high-binding affinity for the PSMA receptor are 
added to the development of targeted radionuclide therapy for men with 
prostate cancer. It is high quality and highly specific for PET imaging.  
Most commonly diagnosed cancer among women in the world is breast 
cancer, meanwhile for men the top cancer diagnose is prostate cancer. 
Mostly they already going through various types of treatment such as 
radical prostatectomy, primary radiotherapy, treatment include androgen 
deprivation therapy and chemotherapy. However, the progress will 
advance to metastatic disease which is no curative treatment exist. It is 
possible of conducting a targeted radionuclide therapy such as Lituteium-
177 PSMA as a choice of treatment for prostate cancer patient. 
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PSMA is a 750 amino acid type II transmembrane glycoprotein. It plays 
many cellular functions such as act as an enzyme involved in nutrient 
uptake. It also plays an important role during cell migration, cell survival 
and proliferation. This PSMA will increase the chance of patient getting 
Lutetium -177 PSMA. The PSMA receptor is going through some 
internal process. During this process, it allows endocytosis of bound 
proteins on the cell surface into an endosomal compartment. By doing 
that, PSMA can be concentrated within the cell. Furthermore, PSMA not 
only can be used for prostate, it can be used for other parts of the body 
including small intestine, salivary glands and proximal renal tubules. 
There is still radiation dose delivered to them when PSMA is used for the 
radionuclide therapy.    
 
The cancer area should be compatible with the emission characteristics 
of a therapeutic radionuclide in order to treat the cancer precisely rather 
than the tissue around it. The medium energy of beta emitter, maximum 
energy and maximal penetration tissue of Lutetium-177 is 490 keV, 
energy of 0.5 MeV and 2 mm of penetration, respectively. Shorter beta-
range is better compared with longer beta-range because it provides 
better irradiation of small tumors. Ex vivo imaging can be conducted due 
to gamma emission from Lutetium-177. As a result, there is a lot of 
information gathered that can be used to know the location of the cancer 
and dosimetry. The efficiency of the targeted radionuclide therapies can 
be improvised by using the patient specific dosimetry. The correct 
amount of dose given can give a huge impact towards the patient. Kidney, 
salivary and lacrimal glands are the particular concern in Lutetium-177 
PSMA treatment. This is due to the suffering of radiation dosing that is 
caused by physiological behavior of the therapeutic peptide. Image-based 
dosimetry at each cycle of treatment can be considered by a patient. In 
order to form the rate of activity accumulation and depletion in each 
organ of interest, the imaging patients at multiple time points must be 
required. As a result, the dose can be estimated. The more time points 
that are acquires, the more accurate the dose estimates. 
 
After receiving the treatment, 30% of the men reported that they had dry 
mouth. Other than that, 25% of them have been going through fatigue. 
Normally 24 – 48 hours after injection, going through nausea is also a 
common side effect. The serious side effect related to Lutetium-177 
PSMA therapy is haematological toxicity. A man with a heavy burden of 
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skeletal metastases and borderline marrow function is more likely to have 
that side effect. There is a decreasing in haemoglobin or platelets. A man 
with no high burden of skeletal metastases does not going through that 
side effect because of longer particle range of Lutetium-177 compared to 
alpha emitters. A man with extensive metastatic bone disease is likely to 
have higher radiation dose of Lutetium-177 around their bone marrow.    
 
3.2 CONCLUSION 
 
Lutetium-177 PSMA is very useful in order to treat men with a prostate 
cancer. It has a low toxicity and well tolerated with men with end stage 
of metastatic disease. The other treatments of prostate cancer such as 
chemotherapy, external beam radiotherapy and androgen blockage does 
not give some benefits to the patients compared with Lutetium-177 
PSMA therapy. Then, Lutetium-177 Dotatate is very useful in order to 
treat a patient with a gastroenteropancreatic neuroendocrine tumor 
compared with the traditional somastostatin analogues. It is harmless to 
the patient and does not have side effect from it specifically. The side 
effect received commonly from the intake of amino acid. 
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CHAPTER 4 
 
 IRIDIUM-192 
 
Nor Amira Ahmad Asri 
 
4.0 INTRODUCTION 
 
Iridium is a silvery white metal, named after the Latin word for 
"rainbow" because its salts are highly colored. Iridium is brittle and hard 
with low ductility, makes it very difficult to machine and form. It is quite 
dense, about twice as dense as lead, and occurs in nature as two stable 
isotopes, Ir-191 and Ir-193. Iridium-193 is the most prevalent isotopic 
form, comprising about 63% of natural iridium, with Iridium-191 
accounting for the balance. Radioisotope Ir-192 is a man-made 
radioactive element that is produced by nonradioactive Iridium metal in 
a nuclear reactor. The strength (or specific activity) of a resulting Ir-192 
is related to the amount of neutron irradiation and length of time to which 
the natural-abundance iridium metal is exposed. During irradiation only 
the stable isotope Ir-191 is activated to produce Ir-192 by absorbing a 
neutron. Radioactive Ir-192 has a half-life of 73.83 days. The lifetime of 
this radioactive element is 106.51 days. 
 
Its decay modes are Beta Particles and Gamma Radiation. It decays 
95.13% of the time through negative beta emission to 192Pt (daughter 
nuclide). For the remaining 4.87% of the time, it decays through electron 
capture to 192Os. A gamma photon with an average energy of 0.38 MeV 
(max 1.06 MeV) is released in the process. Iridium-192 is a radioactive 
iridium isotope that always used for high dose rate brachytherapy 
applications. New isotopes such as cobalt-60, caesium-137 and iridium-
192 became available for Industrial Radiography once World War II 
ended. Consequently, the use of radon and radium decreased. The 
specific activity of iridium is differs depending on the concentration of 
Iridium-192 in the source. For applications of high dose, its specific 
activity is 2.4×102 TeV/g.  
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For commercial use, Iridium-192 is produced in a nuclear reactor by 
reaction of iridium-191 with neutrons. This technique has numerous 
benefits and it ensures minimal generation of unwanted isotopes and 
large cross section of isotopes for interaction of neutrons. As a result, 
high concentration of iridium-192 is produced comparatively easily. 
Iridium-192 is a radioactive substance, so, necessary safeguards must be 
taken while using it. In order to avoid an accidential exposure or misuse, 
It should be kept at the safe place. If there is accidential exposure occur, 
victims should remove clothes and discard them permanently and it is 
important for victim to take showers. Immediate medical help should be 
sought. 
 
There are many advantages of using this radioactive element:  
• Its application can be tailored to high or low dose rate, as per 
requirement.  
• Relatively easy to manufacture.  
• Has a stable daughter product. 
• Can be reused. 
 
The disadvantages of this element are:  
• Broad spectrum of photons is emitted during the emission 
process.  
• Involves frequent recalibrations as a consequence of 
radioactive decay.  
• Needs replacement after every three to four months 
 
4.1 APPLICATIONS 
 
Radiation is used in nuclear medicine to provide information about the 
functioning of a person's specific organs, or to treat disease. The 
information is used by physicians to make a quick diagnosis of the 
patient's illness. The thyroid, bones, heart, liver, and many other organs 
can be easily imaged, and disorders in their function revealed. To treat 
diseased organs, or tumours, in certain case the radiation can be used. 
   
The uses of radioisotopes in therapy are comparatively few, but 
nevertheless important. Cancerous growths are sensitive to damage by 
radiation. Because of this, some cancerous growths can be controlled or 
eliminated by irradiating the area containing the growth. External 
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irradiation or teletherapy can be carried out using a gamma beam from a 
radioactive cobalt-60 source, though in developed countries the much 
more versatile linear accelerators are now being used as high-energy X-
ray sources (gamma and X-rays are much the same). An external 
radiation procedure is known as gamma knife radiosurgery, and involves 
focusing gamma radiation from 201 sources of Co-60 on a precise area 
of the brain with a cancerous tumour. Worldwide, over 30,000 patients 
are treated annually, generally as outpatients. Teletherapy is effective in 
the ablation of tumours rather than their removal it is not finely tuned. 
Internal radionuclide therapy is administered by planting a small 
radiation source, usually a gamma or beta emitter, in the target area. 
Short-range radiotherapy is known as brachytherapy, and this is 
becoming the main means of treatment. Iodine-131 is commonly used to 
treat thyroid cancer, probably the most successful kind of cancer 
treatment. It is also used to treat non-malignant thyroid disorders.  
 
Basically in the head and breast, we implant the iridium-192 in the form 
of wire and it is introduced to the target area through a catheter. This wire 
is removed to shielded storage after the administering the correct dose. 
For early stage prostate cancer, the permanent implant seeds of iodine-
125 or palladium-103 are used in brachytherapy. Alternatively, needles 
with more-radioactive Ir-192 may be inserted for up to 15 minutes, two 
or three times. Brachytherapy procedures give less radiation to the body, 
are more localized to the target tumour, and are cost effective.  
 
Radioactive implants have offered a therapeutic option in the treatment 
of oral cancers for over 70 years and have significant theoretical 
advantages when compared, both with surgery, and with external beam 
radiation therapy, in that they allow delivery of a high local dose of 
radiation to the tumour without the need to destroy local anatomy and 
with- out inducing xerostomia in the majority of cases.Iridium-192, in 
particular, offers advantages when compared with the classic alternatives 
of radium or caesium in terms of smaller diameter of implanted source, 
easier radiation protection, and better geometry. 
 
Iridium-192 is used as a source of gamma radiation for curing cancer 
with the application of brachytherapy. Brachytherapy is a type of 
radiotherapy that involves the placement of a sealed radioactive source 
inside or adjacent to the region that requires treatment. Iridium-192 is 
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used medically in brachytherapy to treat various types of cancer 
including cancer of the lungs, head, neck, mouth, tongue and throat, and 
treatment of vascular constriction. Brachytherapy is a method of 
radiation treatment in which sealed sources are used to deliver a radiation 
dose at a distance of up to a few centimeters by surface, intracavitary or 
interstitial application. Brachytherapy, irradiation at a very close 
distance, is a form of lesions treatment which is based on the insertion of 
sources, in this case activated iridium wires inside tumors. During this 
process, the ionizing radiation destroys the malignant cells very 
efficiently. 
 
4.2 CONCLUSION 
 
Ir-192 implants have medical uses in healthcare industry. These are used 
for curative reasons, primarily in the breast and the head. These implants 
are manufactured in wire form and are introduced into the target area 
through a catheter. The implant wire is removed after being left in place 
for the time required to deliver the desired dose. This procedure is very 
effective at providing localized radiation to the tumor site while 
minimizing the patient’s whole body dose. 
 
REFERENCES 
 
1.  Mccormick, B., Wesson, M. F., Cox, L., Petrek, J. A., Kinne, D. 
W., & Osborne, M. P. (1988). Oncology Intelligence placement at the 
time of wide local excision, 745–748.  
2.  Zeituni, C. A., Lepki, V., & Feher, A. (2003). Iridium-192 
Production for Cancer Treatment, 1– 4. 
 
 
 
 
 
 
 
 
 
 
 
 18 
 
Applications of Radiopharmaceutical in Nuclear Medicine
   ISBN 978-967-2306-01-6
2019 
 
CHAPTER 5  
 
CARBON-11 
 
Mohamad Amirul Hakim Bin Abdul Rahim 
 
5.0 INTRODUCTION 
 
Radiopharmaceutical is a component of medicine or drug which has been 
used for the treatment in the diagnostic or therapeutic needed. It is 
consisting of a bond of radioisotope to an organic molecule. The organic 
molecule conducts the radioisotope to certain either organs, cells or 
tissues. The radioisotope must be choosing for its requirement. 
 
Radioisotopes that has been selected emanate penetrating radiation ray 
such as gamma rays that are used for imaging where the radiation need 
to eliminate from the body before detected by a specific machine known 
as (SPECT/PET cameras). The isotope that are used for imaging emit 
radiation disappear all thoroughly from the body after 1 day. The 
radiation vanishes completely through radioactive decay and normal 
body process which is excretion process. Radioisotopes transfer short 
range of particles normally either alpha or beta. These emitting 
radioisotopes are used for therapy due to their power to lose most of their 
energy over a very short distance which can cause a lot of local damage 
such as cell destruction. This condition is used for the need of therapeutic 
treatment for examples cancer cell destruction, pain treatment in 
consoling care for bone cancer or arthritis. With such as isotopes stay 
further long period in the body than imaging, this will help to increase 
treatment efficiency but maintains limited to several days. 
 
Radiopharmaceutical need to demonstrate its harmlessness for the patient 
and its benefit for the treatment such as some classical drug before been 
access for routine clinical used. Food and Drug Administration (FDA) 
strictly regulated this demonstration process in the United States while 
European Medicines Agency (EMA) in Europe. Normally, the process is 
about 5 to 8 years from the starting discovery to the availability for the 
physicians.11C is a symbol for radioisotope Carbon 11 which is act as a 
tracer that emitted gamma rays. This radioisotope decomposed to Boron 
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11 due to beta plus decay exactly known as positron emission. The 
change from Carbon 11 to Boron 11 result the electron capture and the 
percentage to happen is small which is about 0.19-0.23% of the time. The 
half-life for Carbon 11 is 20.34 minutes.  
 
Carbon 11 can be found in the medical industry. Carbon 11 use as a 
radioisotope for radioactive labeling of molecules in positron emission 
tomography (PET) in the primarily diagnosis of cancer which is help in 
guider for therapeutic response to cancer treatment and pharmacokinetic 
(reaction body has to the drug) analysis of anticancer drugs. PET imaging 
allows a non-invasive (not involving the introduction of instruments into 
the body) to guide metabolic processes and molecular targets, the 
chemically induced tumors while the carbon 11 radiotracer allows for a 
hot/cold substitution of active molecules biologically.  
 
5.1 APPLICATIONS  
 
Carbon 11 which is act as a tracer that emit gamma rays is used in medical 
imaging for the Positron Emission Tomography (PET) machine. A 
positron is emitted and annihilates with a nearby electron and two 
gammas are released back to back. Positron emission tomography is a 
nuclear medicine functional imaging technique that is used to observe 
metabolic processes in the body as an aid to the diagnosis of disease. The 
system detects pairs of gamma rays emitted indirectly by a positron 
emitting radionuclide. Three dimensional images of tracer concentration 
within the body are then constructed by computer analysis. In modern 
PET-CT scanners, three dimensional imaging is often accomplished with 
the aid of a CT X-ray scan performed on the patient during the same 
session in the same machine. 
 
It is also both a medical and research tool. It is used heavily in clinical 
medical imaging of tumours and the search for metastases and for further 
clinical diagnosis of certain diffuse brain diseases such as those causing 
various types of dementias. Besides that, it is also important research tool 
to map normal human brain and heart function and support for the drug 
development. PET also used in pre-clinical studies using animals where 
it allows repeated investigations into the same subjects. This is 
particularly valuable in cancer research as it results in an increase in the 
statistical quality of the data and reduces the numbers of animals required 
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for a given study. PET imaging is best performed using dedicated PET 
scanner. It is also possible to acquire PET images using a conventional 
dual-head gamma camera fitted with a coincidence detector. Although 
the quality of gamma camera PET is considerably lower and acquisition 
is slower because this method allows institutions with low demand for 
PET to provide on-site imaging. Instead of referring patients to another 
centre or relying on a visit by a mobile scanner. 
 
Choline C-11 also known as C11-choline is a radiotracer that is injected 
into a patient prior to positron emission tomography (PET) scanning. 
Low-dose, man-made radioactive isotopes are bonded with biologically 
active molecules by replacing a few of their normal carbon atoms with 
radioactive carbon atoms. These molecules are now labeled with a tiny 
amount of radioactivity and called radiotracers. They are drawn to certain 
tissues in the body where they become concentrated. 
 
Prostate cancer cells are hungry for anything that will fuel their rapid 
growth, it is this feature that allows the tumour to be imaged. Prostate 
cancer eagerly takes up choline which is naturally occurring part of the 
B-vitamin complex. The tumour cells need nutrients to multiply quickly 
and they use choline as a kind of building block. It collects in any prostate 
cancer tumours whether located in the prostate, lymph nodes or more 
remote locations. When choline is tagged with a type of radioactivity 
called C-11, the PET scanner picks up the exact location of the tracer 
concentrations. As three dimensional images of the target regions are 
processed, the tumors are shown as brightly lit spots or areas. 
 
Choline C-11 has a rapid rate decay as it loses half of its radioactivity 
every 20 minutes, so the tiny amount of original radioactivity is soon 
gone from the patient’s body. As the radiation fades, the body continues 
to process the choline just as it would if it had come from a natural source 
such as broccoli eventually eliminating any waste. 
 
Choline C-11 PET is Food And Drug Administration (FDA)- approved 
for the detection of primary recurrent and metastatic prostate cancer. The 
most common use of choline C-11 PET is in fact identifying cancer that 
has come back after treatment including any spread to the lymph nodes 
or beyond. It is particularly useful in monitoring patients who are on 
androgen deprivation therapy (ADT or hormone blockade) because of 
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recurrent cancer as tumors shrink in size that reduction can be assessed 
by the choline C-11 PET images. 
 
A different radiotracer called Carbon-11 Acetate (C-11 Acetate) shows 
great promise as a way to detect early metastatic PCa before treatment 
and also recurrent PCa after treatment. Like the tracer choline C-11, C-
11 acetate is drawn to prostate cancer cells. C-11 acetate quickly and 
selectively taken up by the membranes of PCa tumor cells whether they 
are located in the gland, prostate bed, lymph nodes or distant organs. 
Within minutes after injection into a vein, the concentrated radioactivity 
in any site is detectable by PET or PET/CT scans. The entire scanning 
process usually takes less than 20 minutes from the time of injection. 
Both C-11 acetate and choline C-11 have a relatively short half-life, 
meaning the radioactivity level quickly diminishes. Thus, they require 
onsite production at imaging centers that are large enough to afford a 
cyclotron the sophisticated technology needed to isolate the atomic ions 
and generate molecular bonds to create the radiotracer. No time must be 
wasted from production to transport to the imaging equipment to 
injection. 
 
Both tracers are often used with a process called PET/CT scan. CT 
(Computerized Tomography) clearly shows anatomical structures 
whereas PET lights up abnormally functioning tissue. When the two 
types of imaging are done together at the same time and fused called 
PET/CT scans, tumors are seen in their precise anatomical soft tissue 
locations (prostate gland, prostate bed, lymph nodes and other organs 
such as liver or lung) though less effective such as in the bone. There are 
two differences between C-11 acetate and choline C-11 such as C-11 
acetate is not yet approved by the FDA for detection of prostate cancer 
so it is still being investigated in a small number of clinical trials and 
though investigational, C-11 acetate appears to outperform choline C-11 
though not hugely. 
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5.2 CONCLUSION 
 
As conclusions, Carbon-11 radiotracers are widely used for the early 
diagnosis of cancer, monitoring therapeutic response to cancer treatment 
and pharmacokinetic investigations of anticancer drugs. 
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CHAPTER 6  
 
CARBON-14 
 
Nur Rosyiidah Nor Azman 
 
6.0 INTRODUCTION 
 
Radiopharmaceutical is a preparation aimed for in-vivo use that contains 
a radionuclide in the form of a simple salt or a complex salt. The 
radionuclides can exist in form of solid, liquid, gas or pseudo gas. The 
form of radiopharmaceuticals in chemical and physical identity is very 
important for targeting certain tissue, binding sites and biochemical 
pathways. A radiopharmaceutical can be defined as a radioactive 
pharmaceuticals agent that used for diagnostic or therapeutic procedures. 
Since three decades ago, the discipline of nuclear pharmacy has become 
highly specialised and contributed to the nuclear medicine practice. 
  
In 1978, the Board of the Pharmaceutical speciality recognised nuclear 
pharmacy that focused on the safe and effective use of radioactive drugs 
or radiopharmaceuticals. The application of radiopharmaceuticals is 
divided to two part. They are diagnostic and therapeutic. Therapeutic part 
is evolving more than 100 radiopharmaceuticals products that applied in 
cardiology, oncology and neurology. While diagnostic part is used for 
infection imaging and nephrology. Radiopharmaceuticals consist of 
drugs and radioactive components. Radionuclides can be stable and not 
stable. The not stable radionuclide is radioactive because their nuclide 
undergo rearrangement and changing to a stable state while giving off 
energy. 
 
The most distinct different between radiopharmaceuticals and traditional 
drugs is lack of pharmacological activity in radiopharmaceuticals. For 
top purposes, radiopharmaceuticals are used as a tracer of physiological 
in human body. There is a very big advantage on radiopharmaceuticals 
where they allow non-invasive monitoring using radioactivity or 
targeting therapeutic irradiation with very little effect on the biological 
process. Thus, it is proven to have an excellent safety record and 
extremely low incidence of adverse effect.  
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Therapeutic radiopharmaceuticals are delivering therapeutic doses of 
ionizing radiation to specific disease sites. Specific radionuclides possess 
particulate emissions to destroy disease tissues. Radioisotopes can be 
used internally or externally. One of the examples of externally used is 
sealed capsule implants in a tissue. By removing the source, the dose 
could be terminated. Internally used of radioisotopes by unsealed source 
making the dose cannot be stopped even though the source already 
removed. The basic of the effective half-live of the isotope, concentration 
of the isotope and the type and energy of radiation emitted can be 
calculated to obtain the total dose.  
 
There is deleterious effect of high energy radiation on human cells used 
in the therapeutic uses. The radioisotopes give few characteristics such 
as have longer life than diagnostic use and also possess higher energy. 
Carbon-14 is one of the examples on the application of the 
radiopharmaceuticals. The medical research care and treatment of the 
radiopharmaceuticals are very useful in helping millions of patients 
throughout the world. Nuclear medicine is a medical specialty that 
involves the use of radioactive isotopes in the diagnosis and the treatment 
of disease. Nuclear medicine enables identifying of noninvasively and 
precisely specific molecular activity within tissues and organs of the 
body. As the result, it facilitates the early detection of disease and the 
immediate monitoring of therapeutic response. In 1935, Enrico Fermi 
discovered that stable elements could be made radioactive by 
bombarding them with neutrons and thus nuclear medicine started 
revolving. The radioisotopes have unstable nuclei and dissipate excess 
energy by emitting gamma and other rays.  
 
In radioisotope scanning, a radioisotope is introduced into the body 
through intravenous injection. The isotope is taken up to different organs 
with different amounts depending on the essentiality. The distribution of 
isotope determined by the radiation it emit and through charting its 
concentration to recognize the presence, size and shape or abnormalities 
in organs. One of the applications is carbon-14. It is useful when studying 
the abnormalities of metabolism that cause diabetes mellitus, gout, 
anemia and acromegaly.    
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Carbon-14 or known as radiocarbon is an organic material that contains 
a radioactive isotope of carbon with an atomic number nucleus 
containing six protons and eight neutrons. The carbon that comprises 
human bodies contains carbon-14 at the same concentration as the 
atmosphere. Carbon-14 can be applied as a radioactive tracer in 
medicine. One of the applications is for a diagnostic test for Helicobacter 
pylori. In the initial variant of the urea breathe test, urea labelled as 
carbon-14 is fed to a patient. In the event of a H. pylori infection, the 
bacteria urease enzyme breaks down the urea into ammonia and 
radioactively-labelled carbon dioxide. The carbon dioxide is detected by 
low-level counting of the patient’s breath.  
 
A radioactive tracer is a chemical compound with one or more atoms that 
have been replaced by a radionuclide and new radioactive decay. It is 
essential to explore the mechanism of chemical reactions by tracing the 
path that the radioisotope follows from reactants to product. Carbon-14 
decays by beta decay. It also has long half-life which is 5730 years. 
Carbon-14 is continuously produced in the upper atmosphere of the earth 
so it occurs at a trace level in the environment. Carbon-14 has been used 
to trace the progress of organic molecules through metabolic pathways. 
The principle behind the use of radioactive tracers is that an atom in a 
chemical compound is replaced by the same chemical element but with 
different atom. The substitution atom is a radioactive isotope. The 
radioactive decay is more energetic than chemical reactions. Thus, it can 
be detected by sensitive radiation detectors such as Geiger counter and 
scintillation counters. 
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6.1 APPLICATIONS 
 
Urease in the human stomach is a mark for the H. pylori which is an 
organism suspected of causing infection that lead to chronic gastritis and 
peptic ulceration. A breath test is a rapid diagnostic that is develop to 
detect the gastric infection of  H. pylori. There are several steps should 
be conduct before doing carbon-14 breath test. 
 
Table 1: List of medicines should be stop before carbon-14 breath test 
 
Purpose Medicine Names When to stop 
taking the 
medicine 
(i) Kills germs in 
your body 
• Antibiotics 30 days before the 
appointment 
(ii) Controls/stops 
diarrhea 
• Pepto Bismol 
• Bismuth 
Subsalicylate 
30 days before the 
appointment 
(iii) Reduces gastric 
acid 
• Prevacid 
(lansoprazole) 
• Losec 
(omeprazole) 
• Pantoloc 
(pantoprazole) 
• Nexium 
(esomeprazole) 
• Tecta 
• Maleate 
• Pariet 
(rebeprazole) 
• Dexilant 
(dexlansoprazole) 
14 days before the 
appointment 
(iv) Gastroduodenal 
Cytoprotective 
Agents 
• Sulcralfate 
(Sulcrate, 
Carafate) 
 
14 days before the 
appointment 
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There are a few principles and mechanism for urea breath test. First, the 
patient swallow urea capsule of 1 mCi of labelled radioactive carbon-14. 
The patient needs to provide the breath sample by blowing up a small 
balloon or blowing up small bubbles in a small bottle of breath-collection 
breath. The samples of breath for radioactivity are taken for 30 minutes. 
The carbon-14 urea contains a tiny amount of radioactive material which 
passes out of the patient body in a day or so in the urine and breath. The 
amount of radioactive exposure from the breath test is less than the body 
receive from the environment. 
 
If the H. pylori infection is present in the stomach, carbon is released 
when the solution is broken down in the stomach. Urease activity cause 
hydrolysis of the urea and the carbon-14 is absorbed as carbon dioxide. 
This carbon dioxide enters the patient’s bicarbonate pool and eventually 
is excreted in the breath. The patient body absorbs the carbon and expel 
it when exhale. The carbon molecules in the balloon are detected by using 
special device. The exhalation from the radioactive carbon-14 is transfer 
to the counting vial. The breath sample is mixed with scintillation fluid. 
Then, the carbon-14 is measured by sodium iodide scintillation counter 
and analysed. There is a study on H. pylori where on average; it is proven 
that patients have H. pylori exhaled 20 times more carbon dioxide than 
patients who are not infected. The difference between infected patients 
and not infected is highly significant at all time between two to 30 
minutes after the ingestion of the radionuclide. The carbon-14 breath test 
is considered as important in the non-invasive confirmation of gastric 
infection with H. pylori as in the follow-up of patients after treatment. 
 
There are a few of benefits that can be obtained from the application of 
carbon-14 of pharmaceuticals in nuclear medicine as follows: 
• The test is quick and simple to perform. 
• Breath carbon-14 test is much less expensive than endoscopy. 
• It is the first line procedure for the diagnosis of H. pylori. 
• Tiny amount of radiation material in the body and can pass out 
of body through urine and breathe completely after several days. 
• The breath test is safe and painless. 
• To identify the abnormalities early in the progression of a 
disease. 
• It is not affected by mutations in the target tissues. 
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Other than that, carbon-14 also has its’ disadvantages such as: 
• Carbon-14 has long half-life which is 5730 years. 
• It can produce some allergic reactions. 
• Cannot have anything to eat or drink, including water, 6 hours 
before test appointment. 
• Breath test is not suitable for pregnant women because the 
present of radioactive though very low. 
6.2 CONCLUSION 
 
Nuclear medicine is a sub section of medical imaging that uses small 
amount of radioactive material to diagnose and determine the severity or 
type of disease. The nuclear medicine treatments use radioactive 
materials called radiopharmaceuticals. One examples of diseases treated 
with nuclear medicine procedure is stomach infections such as gastritis 
and ulceration that cause by H. pylori. The application of 
pharmaceuticals is carbon-14 as radioactive source for urea breath test to 
detect the present of H. pylori. 
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CHAPTER 7 
 
INDIUM- 111 
 
Nurul Fadhilah Mohd Yusof 
 
 
7.0 INTRODUCTION 
 
Radiopharmaceutical are the pharmaceuticals that contain radioactive 
substances (radio nuclides or radioisotope) or radioactive drugs for 
diagnostic or therapeutic .It  is a special class of radiochemical 
formulatives that having a high purity ,sterility and apyrogenicity 
suitable for administration to human patients either orally or 
intravenously ,either for diagnosis or therapy .Radiopharmacy studies 
related tp pharmaceutical chemical ,physical,biochemical and  biological 
aspect of radiopharmaceuticals .This report will reviews the data 
available on pharmaceuticals labelled with In 111 .Prior to the general 
availability of these radionuclides to a radiopharmaceutical chemist 
generator  produced In 113 ( 2 /1T = 100 min) had been widely used 
nowadays .Most of radiopharmaceutical used in nuclear medicine may 
be classified into two group which are used for the dynamic functional 
studies for certain organs in the body (eg :  radioiodinated sodium iodide 
for thyroid function studies )  and localized abnormalities in the body (eg 
: localization of tumors ,detection of infacts and visualization of certain 
other abnormal organs). Many reference showed the compound prepared 
with In-111 showed in second group of pharmaceuticals caused of the 
several factor which is the physical characteristics of the radionuclides 
and the method of preparation of their labelled compounds of reported 
data on their clinical applicability. 
 
Indium-111 decay by electron capture and have no beta emission. Its 
physical half- life of 67 hrs respectively are suite for several in vivo 
application. This half- life allows in vivo studies more frequently for 
several days without to administer excessively large quantities of 
radioactive. Considering the gamma photon emission of indium-111 is 
the nuclide choice. The gamma energies of the radionuclides is 247 keV 
are in optimum range of defectability detecting device and the abunce of 
gamma emission 94 % respectively provide 183 photns in every 100 
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disintegrations. Although Indium 111 have higher abundance, but it is 
not in suitable range for detection rather than that gallium. So it is use 
less extensively in clinical applications. Since all compound prepared 
with Indium-111 for in vivo  use are not naturally available in the body, 
it would expected to have different in vivo behavior than the chelating 
agent  (perform several roles : have suitable functional group in their 
molecule, keep biological activity unaltered even the complex formation, 
carry a substantial portion of injected radioactivity to the target tissue, 
the rest radiopharmaceutical clear rapidly  from blood and body through 
excretion). The biological activity of compound is also a direct function 
such as ligand used for formation of covalent bond to the metal ion, the 
organometallic formed is chemically and biologically a new compound. 
 
7.1 APPLICATIONS 
Most of the earlier work on preparation of radioactive indium compound 
for medical application was carried out with a generator that produced 
indium-113 that have half- life 100 min. There are some compounds 
prepared with Indium-111:  
 
7.1.1 Indium-111 Chloride 
  
Indium-111 was first administered to tumor bearing rats and dogs in 
simple ionic form indium chloride. It is used as an ingredient for the 
radiolabelling of certain suitably derivatised proteins which are 
subsequently administered intravenously for a variety of investigative 
purposes using appropriate imaging procedures. It is used extensively for 
the radiolabelling of monoclonal antibodies. Twenty-four to 48 hr after 
injection of the tracer was accumulated in the tumors irrespective of the 
cell type. It was soon apparent from clinical trials that the indium activity 
administered as chloride concentrated in soft tissue tumors as well as in 
bones. It’s have a potential tumor localizing and bone marrow imaging 
agent. The in vivo conversion of ionic indium to indium transferrin is so 
well established, indium-111 citrate has been used in patients for bone 
marrow imaging.  
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7.1.2 Indium-II1 labeled ferric hydroxide 
 
Indium hydroxide is very toxic however, indium does co-precipitate with 
ferric hydroxide which is far less toxic. Therefore, carrier-free It tin-
labeled colloidal ferric hydroxide has been used for lymph node 
scanning. More than 20% of the administered dose has been accumulated 
per gram of an excised lymph node.When the iron concentration and pH 
of the solution is raised, bigger particles, macroaggregates are formed 
which are stabilized with gelatin and which have been used for lung 
scintigraphy.  
 
7.1.3 Indium-111 labeled bleomycin  
 
Since the use of indium chloride as a tumor localizing agent was limited, 
the search for a better compound continued. The physical characteristics 
of the radionuclide were accepted for this application. However, an 
effective carrier was needed which could carry the radionuclide to the 
target tissue. Bleomycin, a mixture of closely related antibiotic 
substances has been shown to have cytostatic properties on malignant 
cells in culture and therapeutic effects on artificially induced tumors in 
animals. Intravenously administered bleomycin clears rapidly from the 
circulating blood and excreted in the urine within 24 hr. These 
characteristics of the compound make it a highly suitable agent to 
localize tumors. However, two more important criteria must be satisfied. 
First, bleomycin should form a complex with a radionuclide of such a 
thermodynamic stability that it would be able to carry the radioactivity 
to the target. Second, the newly formed compound should retain the 
biological properties of the basic organic molecule.  
 
7.1.4 Indium-111 Oxine   
 
Indium-111 is used in specialized diagnostic applications, for example, 
with indium-111 labelled antibodies. Indium-111 oxine is also useful for 
labelling blood cell components. Other applications include labelling of 
platelets for thrombus detection, labelled leukocytes for localization of 
inflammation and abscesses.  
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7.2 CONCLUSION 
 
Indium-111 is commonly used in nuclear medicine diagnostic imaging 
by radiolabelling target molecule. It is also can be used to localization of 
tumor, WBC scan imaging for bone damaging and imaging lymph nodes. 
For instance, Indium-111 Chloride solution have been used in nuclear 
medicine to bind antibodies typically use chelate agent to bind 
radionuclide to target molecule which manufactured to desired product.  
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CHAPTER 8 
 
STRONTIUM-89 
 
Siti Fairuz Mat Radzi 
 
8.0 INTRODUCTION 
 
Radiopharmaceutical is developing into more crucial field of medicine. 
The application of global pharmaceutical in market is estimated to 
increase from $4.9 billion dollar in 2010 to 7.9 billion dollar in 2011. 
There is a significant increase in the global demand in 
radiopharmaceutical field, with the increase of disease related to cardiac, 
neurological and cancer disease. Radiopharmaceutical consists of drug 
component and a radioactive component or substances such as 
radioisotope and molecules labelled with radioisotopes, which are 
currently use in both diagnosis and therapy. Radionuclides refer to 
substances that have same number of protons but different number of 
neutrons. Unstable radionuclide causes their nuclei to undergo 
rearrangement while changing to a stable state and energy is give off.  
Most radionuclides contain a component that emits gamma radiation.  
Radiopharmaceuticals are the main component of nuclear medicine 
practice, where it was administered in diagnosing, managing and treating 
various types of diseases.  The obvious distinction between 
radiopharmaceuticals and traditional drugs is the lack of effect of 
pharmacological activity on human bodies as the part of pharmaceutical. 
Various radiopharmaceuticals have been developed that have different 
targeting mechanisms or routes. Some are given in the simplest salt form 
as non-invasive diagnostic imaging agents to provide functional and 
structural information about organs and diseased tissues. This became 
their main advantage, which is by allowing non-invasive external 
monitoring or targeted therapeutic irradiation, the effect on the biological 
processes in the body was minimized. Radiopharmaceutical was 
recorded as having an excellent safety record and their incidence of side 
effects is extremely low. They may be given to the patients in several 
ways such as orally or placed into the eyes or the bladder.   
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Radioisotopes may be used internally or externally in intensive purpose 
s of radiopharmaceutical, which have been used widely as tracers of 
physiologic processes. If the radioisotope were implanted in sealed 
capsules in a tissue, was applied externally; the dose could be terminated 
by the removal of the sources. If the radioisotope were implanted in an 
unsealed capsule, was applied internally; the dose cannot be stopped by 
the removal of the sources, and the dose tend to possess higher energy.  
Radiopharmaceutical are widely used in diagnostic and therapeutic area 
of human diseases, nearly 95% of pharmaceutical are used for diagnostic 
purposes, while the other 5% are usually used as therapeutic purposes. 
Since radiopharmaceutical was use Nuclear pharmacy or radio pharmacy 
has positively contributed to in nuclear medicine area. With recognition 
from Board of the Pharmaceutical in 1978, nuclear pharmacy has been 
used widely with specialities focus on the safe and effective use of 
radioactive drugs and radiopharmaceutical to treat various kind of 
disease on various part of body. Radiopharmaceutical is actually a 
radioactive pharmaceutical agent that is used for diagnostic and 
therapeutic procedures.  Therapeutic procedures are a procedure that is 
applied to a patient when injury or illness causes the patient’s body 
function to decline. In radiopharmaceutical, therapeutic procedure is 
referred to as therapeutic radiopharmaceutical where molecules designed 
to deliver therapeutic doses of ionizing radiation such as alpha and beta, 
to specific diseased sites. Radiopharmaceutical have evolved from the 
concept that certain radio nuclides possessing emission such as alpha and 
beta radiations or Auger electrons which is a low energy low-range 
electron, be able to possess the ability to destroy diseased tissues.  These 
procedures contribute to either curative which means that the procedures 
can cure the disease, or palliative which means that the procedures can 
relieving or alleviating pain without dealing with the underlying cause.  
 
Unlike intravenous injections (IV) or infusion that used needle or tube to 
send medication through veins, radiopharmaceuticals are deliberately 
particulate to achieve site-specific localization of radioactivity in the 
body. In therapeutic procedures, high energy radiations are sometimes 
used on human cells. Therapeutic radioisotopes are generally longer 
lived than those in diagnostic use and possess higher energies.  There are 
several examples that prostrate the use of radiopharmaceutical in 
therapeutic procedures such as Non-Hodgkin’s Lymphoma Therapy. In 
therapeutic treatments for Non-Hodgkin’s Lymphoma Therapy, a 
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radioisotope called radioimmunotherapy (RIT) are given and attached it 
to an antibody in order to deliver radioactivity to specific cells are. 
Radiopharmaceuticals I-131 tositumomab and Y-90 ibritumomab and 
Y90epratuzunab are used to treat Non-Hodgkin’s lymphoma. Rhenium 
186 (3.8 d) used for pain relief in bone cancer. Beta emitter with weak 
gamma for imaging.  Iridium 192 (74 d) supplied in wire form for use as 
aninternal radiotherapy source for cancer treatment (used then removed). 
Palladium 103 (17 d) used to make brachytherapy permanent implant 
seeds for early stage prostate cancer. Yttrium 90 (64 h) used for cancer 
brachytherapy and as silicate colloid for the relieving.  
 
Diagnostic radiopharmaceutical is used by consuming radionuclides into 
the body. Physicians identified several chemicals which are absorbed by 
specific organs. For example, thyroid takes up iodine or the brain 
consumes quantities of glucose. Radiopharmacists are able to attach 
various radioisotopes to biologically active substances. Once a 
radioactive form of one of these substances enters the body, it will 
incorporate into the normal biological processes and excreted in the usual 
ways. Thus, it can be used to examine blood flow to the brain, functioning 
of the liver, lungs, heart or kidneys, to assess bone growth, and to confirm 
other diagnostic procedures. For example, Iodine- 131 (with half-life of 
8 days) use in diagnostic to study the function of the thyroid gland, it also 
plays an important part in scanning the thyroid for determining size, 
position and possible tumour location. The radiation dose received by 
patients is medically insignificant as the amount of the 
radiopharmaceutical that given is limited to obtain the required 
information before its decay.  Usually, patients will not feel any 
discomfort during the test and there will be no trace left after the test was 
done.  With the non-invasive feature of this technology and its ability to 
observe an organ functioning from outside the body is the main point that 
makes this technique a powerful diagnostic tool. A radioisotope used for 
diagnosis must emit gamma rays of sufficient energy to escape from the 
body and it must have a half-life short enough for it to decay away soon 
after imaging is completed.   
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There are several examples that indicate the use of radiopharmaceutical 
in diagnostic procedures such as Chromium-51 (28 d) as chromium 
chloride injection: Used to label red blood cells and quantify 
gastrointestinal protein loss cyanocobalamine preparation used for 
diagnosis of pernicious anaemia. Dysprosium- 65 (2 h) used as an 
aggregated hydroxide for synovectomy treatment of arthritis. Floufine- 
18 Asfluoro-2 -Deoxy D-Gluocose (fdg) used for cxerebral, myocardial 
and tumor gluocose metabolism. Holmium-166 (26 h) being developed 
for diagnosis and treatment of liver tumours. Iodine-125 (60 d) as 
iothalamate sodium used diagnostically to evaluate the filtration rate of 
kidneys and to diagnose deep vein thrombosis in the leg. It is also widely 
used in radioimmuno assays to show the presence of hormones in minute 
quantities. 
 
8.1 APPLICATIONS 
 
Strontium- 89 is commonly used in relieving the bone pain that occur 
with certain kinds of cancer. Strontium- 89 will be taken up in the 
cancerous area on bone and gives off the radiation that helps provide 
relief of pain. The prescription will be given on by or under the direct 
supervision of doctor with specialized training in nuclear medicine or 
radiation oncology.  Strontium 89 or better known as Metastron is a 
sterile, non-pyrogenic, aqueous solution of Strontium-89 Chloride for 
intravenous administration. The solution contains no preservative. Each 
milliliter contains: 
 
• Strontium Chloride 10.9 - 22.6 mg   
• Water for Injection q.s. to 1 mL   
• The radioactive concentration is 37 MBq/mL, 1 mCi/mL 
• Specific activity is 2.966.17 MBq/mg, 80-167 μCi/mg at 
calibration  
• The pH of the solution is 4 - 7.5  
The recommended dose of Metastron is 148 MBq, 4 mCi, administered 
by slow intravenous injection (1-2 minutes). Alternatively, a dose of 1.5 
-2.2 MBq/kg, 40-60 μCi/kg body weight may be used. Strontium 89 are 
commonly used for patient that suffers from cancer and eventually 
develop into bone metastasis. Bone metastasis occurs when cancer cells 
break away from the original tumour and spread to the bones, where they 
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begin to multiply. The radionuclides were used to alleviate or relieve pain 
(palliation) from skeletal metastases.   Having high rank among cancer 
specialist, Strontium 89 has been proven for improving patients’ quality 
of life and its favourable side effects profile, according to a survey 
conducted in conjunction with the annual meeting of the American 
Society for Therapeutic Radiology and Oncology (ASTRO). More than 
90% of the radiation oncologists who have prescribed Metastron to their 
patients found that their patients were favourable towards the product. 
As Strontium-89 decays, it will emit beta emission with half-life of 50.5 
days. The maximum beta energy is 1.463 MeV which is 100% while the 
average decay energy is 0.58 MeV. The maximum range of penetration 
of beta from Strontium-89 in tissue is approximately 8 mm. The 
following table shows radioactive decay factors to be applied to the stated 
value for radioactive concentration at calibration. 
 
Just like the behaviour of calcium as it clears rapidly from the blood and 
selectively localizing in bone material, through intravenous injection, 
strontium- 89 behave the same way.  The uptake of strontium 89 occurs 
commonly in active osteogenesis in human body. Therefore, the primary 
bone tumours and areas of metastatc involvement can accumulate greater 
concentrations of strontium compared to surrounding normal bone. The 
mechanism of strontium89 is unknown, some believe that local 
irradiation stops the tumour from producing pain-producing enzymes, 
while some believe that it may act through suppression of tumour growth. 
Even though strontium 89 could alleviate pain, it could not cure cancer. 
Dose injected will retain in metastatic bone lesions longer than normal 
bones, about 2 weeks. Over half of the dose will retain in bones for 
patient with extensive skeletal metastases. The excretion of strontium 89 
from human body occur in two pathways; urinary and faeces. Twothirds 
of the dose will be excreted through urinary, meanwhile another one-
third will be excreted through faeces. Patients without bone lesions tend 
to excrete through urinary and urinary excretion is greatest in the first 
two days after the injection. Strontium 89 emit beta and selectively 
irradiates sites of metastatic bone involvement with limited radiation 
effected the soft tissue around the bone lesions. It have been recorded 
that in multicenter Canadian placebo-controlled trial with 126 patients, a 
single injection of Metastron  relief a higher percentage of pain compared 
to a single injection of placebo.  
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It is not recommended to use Metastron if the patients suffer with serious 
compromised bone marrow due to prior therapy unless the benefit of the 
Metastron could weight out the risks. Bone marrow toxicity is one of the 
side effects to be expected from Metastron, particularly white blood cells 
and platelets. Therefore, it was necessary for patients to undergo blood 
cell counts be monitores at least once a week. Usually, platelets will be 
depressed by 30% from original counts. Meanwhile, white blood cells 
are usually depressed to various level compared to original counts. But, 
the level of blood counts will recover approximately six months after 
treatment unless the patient’s disease or additional therapy intervenes.  
Dose and patient verification is needed before administration because 
Metastron deliver a high dose of radioactivity. Moreover, the prescribed 
dose for pregnant woman should be administered as the metastron might 
harm the fetus since there is adequate studies that shows Metastron could 
be harmful or not to the fetus. Patients should be prepared to any potential 
hazard to the fetus.  
 
8.2 CONCLUSION 
 
Metastron are not for use in patients with cancer not involving bone. 
 
• Metastron was advised to be prescribed to patient with platelet 
counts above 60,000 and white cell counts above 2,400, if the 
blood cell counts appear to be below than that, caution should 
be taken.  
• Metastron should be handled with care and appropriate safety 
measured should be taken to minimize radiation to clinical 
personnel.  
• Since the pain relief was delayed approximately from 7 to 20 
days post injection, patients with very short life expectancy is 
not recommended.  
• Special precautions, such as urinary catheterization, should be 
taken following administration to patients who are not able to 
control over urination or defecation in order to reduce the risk 
of radioactive contamination of clothing, bed linen and the 
patient’s environment.   
• Metastron is excreted primarily by the kidneys. Therefore, 
patients with renal dysfunction, the possible risks of 
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administering Metastron should be weighed against the possible 
benefits. 
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CHAPTER 9 
 
RUBIDIUM-82 
 
Nor Farah Amirah Nor Azman 
 
9.0 INTRODUCTION 
 
In year 1859, Robert Bunsen and Gustav Kirchoff who are the German 
Chemistry invented the spectroscope and new age of chemical analysis 
door is open. During the combusting various metals and salts, Bunsen 
burner had been developed the colour of the flames. The wavelength of 
the emission of spectrum can be separated by using external light sources 
and prism.  In year 1861, rubidium was discovered after first major 
discovery of caesium, small content rubidium was found when mineral 
lepidolite was burnt when both Robert Bunsen and Gustav Kirchoff 
detected the flame produced. Rubidium is name as relates to the colour 
seen after excitation of single electron in its shell, and rubidium first 
name is rubidius which is mean as deepest red.  
 
Rubidium is abandon element in earth crust and actually one of our 
commoner elements with a concentration around 90 parts per million. 
Most of rubidium has the primary goal of producing lithium and is 
derived as product of lepidolite extraction. To obtain the pure rubidium, 
metallic calcium with reduction of rubidium chloride at around 750 
degree celcius. As group one of the periodic table, rubidium is one of the 
alkaline metals, have one electron in their outer shell. Rubidium is highly 
reactive with oxygen, water and halogens and the state never exceeds +1. 
The impact of the reaction between rubidium and water is very 
impressive between sodium and lithium. It can catch fire spontaneously 
in water and make rubidium to save in inert conditions because can make 
liberated hydrogen ignite. Rubidium are soft metals with low melting 
points, being silvery and can melting at 39 degree celcius. The half- life 
of the rubidium is 50 billion years and can decays to form strontium-87. 
Other than in medical application, rubidium also can be used in atomic 
clocks which employs the transition between two hyperfine energy 
states. The clocks uses microwaves radiation which is tuned until it 
matches the hyperfine transition which mean it can calibrate time by 
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itself.  During the process investigation of unusual properties of low 
temperature fluids, rubidium is choosen because of rubidium have zero 
viscosity and able to spontaneously flow out of their containers. 
Rubidium- 87 is used to produce advanced technology which is make 
cooling elements close to absolute zero feasible. Other than use in atomic 
clocks, rubidium can be used in mobile phone capacitor which is 
components that do not crack up under pressure.  
 
Starting from 1920, rubidium was used more frequently in research, 
chemical reactions and electronic applications. Rubidium was extracted 
by electrolysis from the surrounding mineral. To extract enough 
rubidium for study its properties, only 150 kilograms of lepidolite ore 
was needed. Rubidium is known as electropositive because it tended to 
form positive ion than potassium and another alkali metal. Rubidium can 
re-arranging the atoms into a new crystalline structure where the new 
structure good in insulating, superconducting, magnetic and metallic. 
Rubidium can transform insulator into conductor by applying pressure. 
 
9.1 APPLICATIONS 
 
9.1.1 Rubidium -82 As Nuclear Medicine Generator  
 
There are many essential of Rb-82 in nuclear medicine for examples, 
adequate and reasonably  priced supply of Sr-82, replaceable inorganic 
ion exchange columns charged with 100-200 mCi of Sr-82, simple and 
reliable operation of the generator over extended elution volumes and can 
be used in long term period, and maintaining a sterile and pyrogen free 
eluate for safe i.v. injection.  Advanced intracoronary imaging techniques 
for examples intravascular ultrasound [IVUS] and optical coherence 
tomography which provide superior sensitivity for the detection of 
cardiac allograft vasculopathy (CAV), however their application is 
limited by extensive cost, limited expertise, and their restricted ability to 
evaluate only the epicardial vessels. In addition, both coronary 
angiography and advanced intracoronary imaging techniques require 
invasive instrumentation, which carry infrequent, but significant risk for 
complications. Due of that, rubidium is a good application to replace 
because it high in quality of image, affordable price and can be used in 
many process. Radionuclide generators for example Rb -82, provide an 
inexpensive alternative to on-site dedicated cyclotrons for the production 
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of short-lived positron-emitting radionuclides. An alternative approach 
in a commercial Rb-82 generator, is to use a radioactive detector to 
integrate the dose of Rb -82 delivered and to electronically trigger a shut-
off or bypass valve to stop the infusion of radioactivity at the desired 
level.   
 
9.1.2 Rubidium- 82 In Positron Emission Tomography (PET)   
         Myocardial  
 
In modern industrialized countries with an aging population, 
cardiovascular disease or coronary artery disease (CAD) is the leading 
cause of death. For detect high-risk patients or vulnerable patients, it is 
desirable to develop accurate and widely available noninvasive 
diagnostic testing for those patients. For identifying patients with CAD 
and for predicting their future cardiovascular events, techniques for 
evaluating myocardial perfusion are important. An advanced nuclear 
imaging technology was introduced which is positron emission 
tomography (PET). In North America in clinical practice, Rubidium-82 
(82Rb) has been used as generator of positron emission tomography 
(PET) myocardial perfusion tracer without immediate access to an on-
site cyclotron and nowadays, rubidium-82 become available at several 
cardiovascular centers in Europe and Japan. Before this, PET has been 
less used in medical because of expensive of onsite cyclotron for 
radioisotope production and expensive PET scanners, however after 
development of less expensive, it is widely used.   
 
Since the late 1950, rubidium used in the context of myocardial perfusion 
have been studied. In relation to myocardial perfusion, the rubidium is 
extracted from blood and is taken up myocardium which requires high of 
energy. Similar to conventional single photon emission computed 
tomography (SPECT) myocardial perfusion imaging (MPI), rubidium-82 
can generate a clear perfusion image because it is an extractable tracer 
and it can identify viable myocardium when the cell membrane was 
disruption during the rapid washout of Rb -82 from the tissue. The 
radiation exposures for patients is limited around (5.5mSv for 60mCi) 
because it has short half- life, the total study time can be reduced as the 
image acquisition requires is short after tracer administration. Rb-82 has 
lower extract fraction which may affect the hyperemic flow 
measurements, and this will make the image resolution reduced. 
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However, data support with flow quantification of Rb -82 will be 
feasible, accurate and reproducible because of rubidium activity can be 
infused over a longer interval to reduce the peak dead time-losses and the 
PET imaging will be displayed in three dimensional mode.   
 
When using rubidium in PET, quick reconstruction of the rest uptake 
frame can be often detected even the patient is still on the bed, instructed 
the patient to eat or drink water before repeating the image acquisition. 
PET also provides reliable images, particularly in large patients even 
though the patient with large breast and arm present in the field of view. 
By using rubidium in PET, can be used to see your heart images and can 
shows how much blood getting to your heart muscle when rest or 
exercise. 
 
9.1.3 Rubidium- 82 In Breast Cancer   
 
Biomarkers have the potential to aid in the risk assessment, diagnosis, 
early detection, prognosis and prevention of the breast cancer is 
important and numerous reported have been on biomarkers, but only a 
few have been practice and used in clinical. For the breast cancer risk, 
shows that genetic risk factors change little of the level of predicted 
breast cancer risk especially for woman.  The food content of rubidium 
was inversely associated with cancer incidence in early 1974 was found 
among Hopi Indians. Tumor volume was significantly reduced in vivo 
study after the administration of rubidium carbonate in mice. Levels of 
rubidium in tumor tissue were significantly higher than in the normal 
tissue or particularly breast tumor tissues.  Due of that, rubidium is used 
in tumor through intake of rubidium in form of food with control dose. 
 
In human, rubidium is natural substances and micronutrient like 
selenium, for evaluating its anticancer efficacy, it would be meaningful 
to compare rubidium levels in biological samples between cancer 
patients and normal control patients and it also important to know the 
application of the rubidium as application as a biomarker of the risk 
assessment.  Through urine, rubidium is excreted and urine concentration 
is a good indicator for the exposure of the rubidium. The acid toxins 
leaking out of the tumor mass was neutralized and renders them to 
become nontoxic this because the presence of rubidium salts in the body 
fluids. In the colorectal patients, the concentrations of the rubidium in 
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whole blood is much lower than the patients in healthy controls. The 
rubidium was sequestered by the tumor so the levels of rubidium in 
patient’s serum and urine is low. 
 
9.1.4 Rubidium In Immune Response  
 
Rubidium- 82 is being tested as antidepressants, as the effects of drugs 
on responses to lymphocyte mitogens and on natural killer (NK) cell 
activities were compared, in the absence of mitogens, the uptake of 
thymidine by spleen cells from rats treated with rubidium was greater 
than that of untreated controls. Spleen cells from treated groups of 
rubidium exhibited significantly greater proliferative responses to 
lipopolysaccharide (LPS) than those from untreated controls. The 
previous reports of tests with Rb-82 found augmented responses to B-
cell mitogens in vitro and enhanced antibody responses in vivo. 
Rubidium suppressed responses to LPS when added in vitro. Other than 
that, in vivo, Rb-82 has effects in addition to or different from those 
detected in vitro.  The drugs stimulated the differentiation of monocytes 
and granulocytes in the rats and due to this differentiation attributed to 
different effects on the metabolism of cations in body which is a factor 
that does influence the stimulation of lymphocytes.  
 
The capacity of Rb-82 to modulate proliferative responses is a new 
finding which warrants testing the effects of this drug on other immune 
responses including specific acquired immunity and suggests that future 
therapeutic trials should include a consideration of potential 
immunologic effects.  Rb-82 has been reported to have opposite effects 
in some of their behavioral and biochemical actions and also have 
different effects on some cellular enzymes such as adenylate cyclase and 
superoxide dismutase. 
 
9.1.5 Health Effect Of Rubidium  
 
• Moderately toxic by ingestion.  
• As the rubidium is reactive metal with water and oxygen, if the 
rubidium is ignites, it will cause thermal burns.  
• Over exposure of patients to rubidium can result in skin and 
eye burns.  
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• Other than that, over exposure can cause failure to gain 
weight, hyper irritation, ataxia, skin ulcers and nervousness.  
• Make sure to tell your doctor, if you have allergies, pediatric, 
geriatric and pregnancy before you consume rubidium to avoid 
any problem occur to your health.  
9.1.6 Uses Of Rubidium Other Than Medical  
 
• Rubidium can extend up to manufacturing photocells, 
electronic tubes such as such as  
• handheld games consoles, laptops and digital camera because 
rubidium good at conducting  
• both heat and electricity and atomic clocks.  
• Act as utilizer in creating glass and ceramic wear.  
• Uses of rubidium metal diversifies as a component in lending a 
purple color to fireworks.  
• Used in laser cooling by rubidium vapor.  
• Rubidium is agile enough to seep into plants. Rubidium enters 
the food chain and becomes  
• a constituent, with daily intake of component ranging from 1 
to 5 mg.  
• Working fluid in vapor turbines. 
9.2 Conclusion 
 
In a conclusion, rubidium is available in nuclear medicine as it is the 
second most electropositive metal and rubidium has no known biological 
role and it is non-toxic. Rubidium can be absorbing from food and 
average person has stores of about half a gram in the body as same as 
potassium. The development of the rubidium generator has progressed to 
the stage where it has been safely applied to PET studies in clinical 
nuclear medicine, in breast cancer and immune response. In Malaysia, 
rubidium usage still in low percent as we rarely used rubidium for treat 
disease. 
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CHAPTER 10 
 
IRON-59 
 
Nurul Farhah Mokhtar Din 
 
10.0 INTRODUCTION 
 
What is meant by radiopharmaceuticals?. Generally, 
radiopharmaceuticals can be defined as a group of pharmaceutical drug 
which contain radioactivity. It is a formation that designated to be used 
through an in-vivo experiment that contains a radionuclide. In can be 
form in a simple salt or a complex. Radiopharmaceutical may be present 
in three kind of form namely solid, liquid or pseudo gas. In-vivo 
experiment is basically an experiment that includes the examination 
involves the living organism. Thus, the chemical and physical identify 
includes the form of radiopharmaceutical is important as it may vary 
according to each treatment. It is because, once a radiopharmaceutical is 
used, it has its own specific tissues target, biochemical pathways and 
binding sites. Radiopharmaceuticals can be used as diagnostic and 
therapeutic purposes and it may depend on what kind of physiochemical 
and the radioactive used. Thus it can reflect based on the properties of 
specified radioactive.  
 
Isotopes are atoms of an elements that have the same number of proton 
but different number of nucleon. It emits radioactive naturally or may be 
produced artificially if it is in unstable state. However, the radioactive 
emitted have its own ability on penetrating with materials that have 
different densities and thickness. It also may kill the cells or causes the 
cell mutation. Moreover, it has a few applications mainly in medicines, 
agriculture, archaeology and industries. As the diseases is found on the 
specific part in patient’ body, he/she may take radioisotopes as one of the 
medical solution. The radiation emitted enables the organ to be easily 
detected and imaged by imaging machine. Thus the diseases may be 
localized and treated. As an example, Iodine-131 is used as a tracer of 
thyroid gland.  
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Basically, nuclear medicine is a modern technique on imaging a disease 
of a patient. It technically been done by injecting a small amount of 
radioactive materials called radiotracers or radiopharmaceuticals into the 
patient’s bloodstream. It even can be taking by patient through inhale or 
swallow the radioactive materials depending on the type of nuclear 
medicine test. A special camera will detect the radiation emitted by those 
radioactive on the specific part of human body according to the properties 
of radioactive itself thus displaying the images of our body through the 
computer. In most centers, nuclear medicines images is displayed on 
computer tomography (CT) or a magnetic resonance imaging (MRI). It 
is done to give a detailed view inside of the human body thus an accurate 
diagnosis could be obtained. Apart from that, this technique gives a 
particular information that might not be able detected by other type 
imaging machine. It possibly to detect the diseases such as cancers, heart 
disease, gastrointestinal, neurological disorders, endocrine and other 
abnormalities potentially in their early stages. Besides diagnoses, 
therapeutic is also may be used in nuclear medicine treatment. For 
example, Iodine-131 is used as radioactive therapy to treat cancer or other 
diseases. 
 
There are some common uses of nuclear medicine treatment. It is used in 
adults to visualize the heart blood flow, detection of coronary artery 
disease, detection of heart transplant rejection and evaluating heart 
function before and after chemotherapy. It may also been use to scan 
lungs for respiratory and blood flow problems.  
 
Table 1 Radioisotopes and it uses 
 
RADIOISOTOPES USES 
Ammonia N-13 Injection is a radioactive diagnostic agent for Positron 
Emission Tomography (PET) indicated for diagnostic 
PET imaging of the myocardium under rest or 
pharmacologic stress conditions to evaluate myocardial 
perfusion in patients with suspected or existing coronary 
artery disease. 
Chromium-51  Chromium chloride injection is used to label red blood 
cells and quantify gastro intestinal protein loss 
cyanocobalamine preparation used for diagnosis of 
pernicious anaemia. 
Dysprosium -165 Used as an aggregated hydroxide for synovectomy 
treatment of arthritis. 
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Fluorine-18 Used for cerebral, myocardial and tumour glucose 
metabolism. 
Holmium-166 Developed for diagnosis and treatment of liver tumours. 
Iodine-125 As iothalamate sodium used diagnostically to evaluate the 
filtration rate of kidneys and to diagnose deep vein 
thrombosis in the leg. It is also widely used in 
radioimmuno assays to show the presence of hormones in 
minute quantities 
Iodine-131  As sodium iodide 131 used as a diagnostic aid for studying 
the function of the thyroid gland and in scanning the 
thyroid for determining size, position and possible tumour 
location. Iodine 131 as sodium iodohippurate as a 
diagnostic for studying kidney function. 
Iron-59 Ferric chloride solution used in studies of iron metabolism 
in the spleen. 
Oxygen-15  Studies of tissue water content and as a tracer for regional 
blood flow. 
Potassium-42 As potassium chloride injection, used for the 
determination of exchangeable potassium in coronary 
blood flow. 
Rubidium-86 Rubidium chloride injection used for determination of 
myocardial blood flow. 
Selenium-75 Used in the form of seleno-methionine to study the 
production of digestive enzymes. 
Sodium-24 As sodium chloride injection to study sodium exchange. 
Xenon-133 Used for pulmonary (lung) ventilation studies. 
Gallium-67 As gallium citrate used for tumour imaging and 
localisation of inflammatory lesions (infections). 
Strontium-89 It delivers radiation to cancer sites and ultimately 
decreases bone pain. The length of treatment depends on 
the types of drugs you are taking, how well your body 
responds to them, and the type of cancer you have. 
Thallium-201 Thallous chloride used for diagnosis of coronary artery 
disease other heart conditions such as heart muscle death 
and for location of low-grade lymphomas. 
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10.1 Applications 
 
Iron-59 symbol is Fe. It consists of 26 protons and 33 neutrons and 
atomic masses of 59. It has a half-life of 46 days. Half-life can be defined 
as when the nucleus of an atom splits into two part and it can only occur 
in an unstable isotope such as Iron-59 and Iodine-123. Iron-59 decays 
into two types of radiation namely beta and gamma radiation. It decays 
as a neutron in its nucleus turns into a proton which called an anti-
neutrino. This force it to emit an electron thus emitting energy and 
radiation. Iron-59 has been figured out to be used as a pharmaceuticals 
in diagnosing the diseases related to blood such as anaemia. It functions 
as a tracer to track the blood cell in the human body. As soon as it been 
injected into the patient’s body, it starts to emit the gamma and beta 
radiation as this radiation is an excellent blood cells tracker.  
 
Besides, iron is a chemical element that is mostly essential to the human 
body. This is because of its primary component of haemoglobin, 
cytochrome and other components of respiratory enzyme systems. In 
order to recover erythrocytes that are destroyed in body processes, as a 
human we should take iron constantly or even a small amount of it in our 
food. Moreover, food is the way on how our body receives the most iron 
supply. Hydrochloric acid that secreted in the stomach functions to 
convert the food for the use in the body. The iron is separated from the 
food by action of the acid thus combining it in a form that compatible 
with the body. 
 
Iron is one of the important trace elements. Its total weight in human 
body is about 3 to 5g. 75% of it is present in the body while the rest is 
present at the liver, bone marrow and muscles. Iron is existing almost in 
all cells. Heme is a group that is the most important iron-containing 
substance. It is a part of protein or enzymes. Meanwhile the non-heme 
iron is transferrin, ferritin and hemosiderin. Iron can be found through 
many sources in food such as liver, meat, egg yolk, green leafy 
vegetables and cereals. Iron is called as a one-way substance as it is 
absorbed and excreted from the small intestine. Iron is absorbed from 
upper small intestine. Moreover, iron is absorbed in three forms namely 
ferrous iron, ferric iron and heme iron. However, iron is mainly absorbed 
in ferrous form. Ferric iron is then reduced with ascorbic acid and 
glutathione of food to more soluble ferrous (Fe²⁺) form which is easy to 
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be absorbed compared to Fe³⁺. Iron is then either be stored in the form of 
ferritin in mucosal cells or been transported across the mucosal cells to 
the plasma in form of transferrin.  
 
There are few factors that increases the iron absorption. The reduction 
form of iron from ferric iron to ferrous form with the help of ascorbic 
acid and cysteine is one of the factor that increases the iron absorption as 
ferrous is the form of iron that mainly being absorbed into the mucosal 
cells. Other than those two, cystatin C and hydrochloric acid may also 
contribute in the process of reduction. In addition to that, the iron 
absorption rate is increases to 2-10 times than the normal rate when body 
is in deficiency state. Apart from that, there are also few factors that 
decreases the iron absorption.  Firstly, it decreases because of the 
presence of phytates and phosphates in the food. Second, the 
achlorohydria factor which is the deficiency in hydrochloric acid results 
in impaired conversion of ferric form of iron to ferrous form. The last 
factor is the presence of gastrointestinal diseases. This disease somehow 
makes the iron absorption decease. For transportation of iron in mucosal 
cells, the iron (Fe²⁺) is entering the mucosal cell by absorption is oxidized 
into ferric form (Fe³⁺) with the help enzyme ferroxidase. The major 
sources of iron in the plasma is from the degraded erythrocytes. Thus, 
Fe³⁺ is combined with apoferritin to form ferritin which is the temporary 
storage of iron. Apoferritin is a colourless crystalline protein that capable 
in storing iron in bodily cells especially in liver by combining with iron 
to form ferritin. Next, the iron may enter the blood stream from the 
mucosal cells.  
 
Iron is absorbed into the plasma in the ferrous state. Thus for being 
transported along the plasma, iron is being oxidized into ferric form with 
the help from copper that contains protein, ceruloplasmin-ferroxidase 
activity. Ferric iron bind with specific iron-binding protein transferrin or 
siderophilin. Thus, iron is being transported in the form of transferrin.  It 
is a plasma protein that transports iron through the blood to the liver, 
spleen and bone marrow. The normal plasma level of transferrin is 250 
μg/dl. One molecule of transferrin can transfer two ferric atom and it has 
a half-life of 7 to 10 days. Total iron binding capacity (TIBC) of 
transferrin is 250-450 μg/dl. In iron deficiency anaemia, as the serum iron 
level decreases, the total iron binding capacity is increases. 
Iron as form of ferritin is stored in liver, spleen and bone marrow. Ferritin 
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act as a temporary storage while it at the mucosal cells and contains about 
23% of iron. However, ferritin in the plasma level is elevated in iron 
overload. Ferritin level in blood represents an index of body iron stores. 
Ferritin is an acute phase reactant protein which elevated in inflammatory 
diseases. There is another iron storage protein called hemosiderin. It can 
hold about 35% of iron in weight. As the iron level increases, 
hemosiderin is accumulated. As for excretion, the normal rate of iron 
excretion is about 1 μg per day. The iron is excreted majorly through the 
intestine. Iron somehow is not excreted through the urine, but through 
the nephrotic syndrome it may losses transferrin thus increasing the loss 
of iron in urine. 
 
Iron deficiency and iron overload are the major disorders of iron 
metabolism. Iron deficiency may cause a reduction in the rate of 
haemoglobin and erythropoiesis and results in iron deficiency anaemia. 
What are the causes of iron deficiency? It is obviously because of the 
insufficient intake of iron. Plus it may happen because of those impaired 
absorption, and chronic blood loss. Iron deficiency anaemia mainly 
happen to a growing children, adolescent girls, and pregnant women. A 
person could do a check-up if he/she is having the symptoms of 
weakness, fatigue and dizziness or a non-specific symptoms such as 
nausea, anorexia, constipation and irregularities of menstrual cycle.  
 
Iron over load is another type of disorders which may causes by 
haemosiderosis, haemochromatosis and iron poisoning. Haemosiderosis 
attribute to the accumulation of hemosiderin in liver and other reticulo-
endothelial system. Besides, there is no serious tissue destruction. 
Haemosiderosis is the initial stage of iron overload. Followed by 
haemochromatosis. It happen as iron is directly deposited into the tissues 
such as liver, spleen, bone marrow and skin. Haemochromatosis may 
happen in two ways namely genetic (primary) or acquired (secondary). 
Genetic haemochromatosis is a heredity disorder that take place due to 
uncontrolled increase in the intestinal absorption of iron from normal 
diet. Iron is deposited as haemosiderin in liver, pancreas, heart and other 
organs. After accumulation, excessive amount of intracellular iron lead 
to tissue injury and organ failure. The acquire haemochromatosis is 
caused by an excessive intake of iron, increased hemolysis and repeated 
blood transfusion. Thus, these shows the studies of iron metabolism 
through Ferro kinetics test. Ferro kinetics is a study of iron metabolism 
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by using radioactive (iron). 
 
10.2 CONCLUSION 
 
In conclusion, there are some advantages and disadvantages of nuclear 
medicine treatment. It benefits the people by providing the detailed 
information about the disease including the details on both function and 
the anatomic structure of the body which is hard to be obtained if using 
the other type of treatment. Plus, the nuclear medicine scans yield is the 
most useful information needed for many diseases so that it is easier to 
be diagnosed and treated. This kind of treatment is less expensive and 
may provide better explanation than the surgery. Moreover, it offers a 
potential to identify a diseases at its earlier stage often before getting the 
symptoms. Somehow, there are some disadvantages of using this 
treatment. There is possibilities of a person to get an allergic due to the 
body allergic problem to those radiopharmaceuticals. However, this case 
is rarely occur and if happen it usually is a mild case. To be prepared, 
that person must tell the nuclear medicine personnel if you have any 
allergies toward the material. In addition, the injection of radiotracer 
might gave a slight pain and redness. Last but not least, women should 
always remember and inform the physician or the operator if you are 
pregnant or might breastfeeding a baby to ensure there is no harmful 
effect to your baby. 
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CHAPTER 11  
 
NITROGEN-13 
 
Nurul Fathihah Abu Bakar 
 
11.0 INTRODUCTION 
 
Nitrogen element was first discovered by Scottish physician Daniel 
Rutherford in 1772. It was discovered as a separable component of air. It 
is a chemical element with atomic number 7 which has atomic weight of 
14.007. The element is colourless, odourless, tasteless and mostly inert 
diatomic gas at standard conditions. It is slightly soluble in water. 
Nitrogen can be found 80% in Earth’s atmosphere by volume which is 
why it has stated as the common element in the universe.   The history of 
nitrogen begins when Daniel Rutherford found the element and called it 
as noxious air. At first, he could not identify it as different chemical 
element, however he can differentiate it from other gases such as ‘fixed 
air’ and carbon dioxide. It is a very inactive gas at room temperature and 
could not combine with oxygen and hydrogen or any other elements but 
could combine with oxygen when there is presence of lightning or a 
spark. Nitrogen has its own radioisotope which is Nitrogen-13 that is 
used in positron emission tomography (PET). This radioisotope has half-
life of 9.97 minutes hence it is made at the PET site. For production of 
nitrogen-13, cyclotron is required. Usually, nitrogen-13 is used in 
myocardial perfusion imaging to tag ammonia during PET procedures.  
Cyclotron is a particle accelerator invented in 1929-1930 to accelerate 
charged particles from the centre along a spiral path which helps the 
production of nitrogen-13. Equation 11.1 explains the reaction occurred 
to produce nitrogen-13.   
  
                                       
1H + 16O → 13N + 4He                               (11.1) 
                                                                      
The process occurred was endothermic reaction. Proton is accelerated by 
a kinetic energy of about 5.55 MeV or higher. 
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Nitrogen-13 plays significant role in CNO cycle. CNO cycle is a carbon 
nitrogen-oxygen cycle. In this cycle, it involves two known sets of fusion 
reactions which converts hydrogen to helium. In this cycle we can see 
the process of nitrogen-13 decays into carbon-13 by releasing neutrino 
and positron.  Commonly, nitrogen-13 is used for PET. It is a nuclear 
medicine functional imaging technique that used to observe metabolic 
processes in body as support to the diagnosis of disease. Nitrogen-13 is 
used as radioactive tracer in this instrument to emit gamma rays 
indirectly which is then detected by the system of PET. It is also used to 
describe the tissue concentration of other types of molecules. 
 
11.1 APPLICATIONS 
 
11.1.1 Validation Of Nitrogen-13 Ammonia Tracer Of  
               Quantification Of Myocardial Blood Flow Using PET  
 
Quantification of myocardial blood flow is essential in determining the 
coronary flow reserve and as parameter for measurement of the 
functional integrity of coronary vasculature. The positron emission 
process using dual photon annihilation allows accurate attenuation 
correction and absolute quantification of temporal behaviour of tissue 
radionuclide in human organisms.  In positron emission tomography, the 
radiotracers that shown the most efficient quantification of myocardial 
blood flow is nitrogen 13-ammonia. This is due to its characteristic that 
is extracted by the myocardium and engaged with a lengthy biological 
half-life.  Nitrogen 13-ammonia is chosen because of its advantages of 
having acceptable tomography count rates and high tissue to blood 
contrast ratios which enables a clear description of the walls of the 
myocardium.  It also gives nonlinear relationship between tracer tissue 
retention and myocardial blood flow.  A new invention of a tracer kinetic 
model has been developed to enable the initial extraction of N-13 into 
extravascular space from myocardial into metabolic conversion to 
glutamine. This application will allow the quantification of blood flow 
over a wide flow range.   The purpose of this application is to validate 
the three compartment kinetic model for myocardial blood flow using N-
13. Then, the results obtained will be compared with another radiotracer, 
oxygen-15. The concentration of nitrogen-13 in the blood pool reached a 
maximum within 30 seconds after tracer administration and declined 
rapidly the first 2 min and then remained constant without approaching 
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zero. Nitrogen-13 in blood is metabolized into amino acids and urea. 
From the study, it has been concluded that when N-13 is compared to O-
15, both show an excellent correlation over a wide flow range that close 
to unity.  
 
11.1.2 Coronary Flow And Flow Reserve By PET Simplified For  
            Clinical Applications Using Nitrogen-13-Ammonia  
 
Coronary flow reserve or also known as CFR is defined as maximum 
flow normalized to resting flow that is reduced by diffuse disease and 
reflects its presence and severity. To monitor the coronary flow, PET is 
used in current pharmacologic to obtain the imaging reflects relative 
distribution of maximum coronary flow in the presence of coronary 
artery disease. From the observation, it is stated on previous research that 
patients with local coronary artery disease have coronary arterial lumens 
that are diffusely 30% to 50% smaller than normal persons.  The benefits 
of using N-13 in the procedures is stated in previous study which is N-13 
has higher prognostic value in comparison to other radiotracer like Rb-
82. However, the disadvantage of using nitrogen-13 is that there might 
be some “role-off” with ammonia uptake which not increasing linearly 
at high coronary blood flows. Thus, the myocardial perfusion 
quantification using N-13 is predictable to underestimate CFR at high 
flow range.   
  
11.1.3 Myocardial Perfusion Imaging  
  
The application of nitrogen-13 as radiotracer is very essential in 
myocardial perfusion imaging. It is a nuclear medicine procedure that 
illustrates the function of heart muscle (myocardium).  It is first 
developed by Dr. Herrmann Blumgart to measure cardiac strength by 
injecting patients with a radioactive compound known as Radium C. The 
substance was injected into venous system and pass through the right 
heart into the lungs then into left heart and out into arterial system where 
it then detected by Wilson chamber. The chamber monitor the circulation 
time of the radioactivity produced. It is concluded from the procedures 
that the longer the circulation time, the weaker the heart. The role of 
radioactive substance, like nitrogen-13 is important in order to determine 
the cardiac physiology (function).   
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11.1.4 Production Of Nitrogen-13-Ammonia By Using 11 Mev  
            Medical Cyclotron  
 
In producing nitrogen-13-ammonia in usable quantities with least 
contamination, a method has been developed in order to realise the 
statement. The system involves a device to produce a proton beam which 
travels along the selected path and strikes the target material in a target 
chamber. The process will produce nitrogen-13 atoms and alpha 
particles. In the early production of N-13-ammonia it was produced from 
alpha particle irradiation and heating of boron nitride in sodium 
hydroxide. Then, it was produced by deuteron irradiation of methane gas 
or metal carbides, but somehow gave low yields. This shows that, this 
method was not too efficient. Thus another method was developed which 
is the proton irradiation of natural water target that involves oxygen 
bombarded with proton that producing nitrogen-13 and alpha particle. 
This is due to the hydrogen abstraction from the target water matrix.  
Another method to produce N-13 was found around year 1991 by 
Wieland et la. They produced the N-13 directly in the water by adding 
free radical scavengers like ethanol, acetic acid and hydrogen to avoid 
the formation of the oxo- anions. The method is involving the use of 
pressurized, dilute aqueous solutions of acetic acid and ethanol.  Previous 
study has stated that combination of hydrogen and ethanol was more 
effective rather stand alone at high beam doses. However, it has limiting 
factor which is the nuclear reaction has very small cross-section of the 
reaction which requires accelerators or cyclotrons with energies that 
higher than 11 MeV.  By using cyclotron, it produced radionuclide by 
irradiation reaction with 11 MeV protons. It bombards oxygen-16 with 
protons and emits alpha particles and nitrogen-13 as final product. The 
nitrogen-13-ammonia is produced from the reduction process of 
nitrogen-13-nitrates and nitrites. It is converted into N-13-ammonia in 
aqueous medium which involving exothermic reaction. 
 
The produced N-13-ammonia is used in myocardial perfusion imaging 
by PET and is approved by The US Food and Drug Administration to 
measure the myocardial and cerebral perfusion. It is also used to label 
glutamine and asparagines for assessment of tissue sustainability.  
Irradiation process is initiated after the target preparation was done. All 
parameters like target pressure, beam current, helium pressure and 
helium flow were examined frequently before each run occurred to 
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ensure proper operation conducted.   
 
11.1.5 Detection And Localization Of Coronary Artery Disease  
            Using Nitrogen-13ammonia  
 
It has been stated that nitrogen-13 is used as tissue tracer to detect the 
coronary artery disease by using positron emission tomography. It is 
approved that using this technique is an accurate detection among others.  
The application of nitrogen-13 can be seen from the methods applied to 
the patients. At first, all the patients that had to undergo the PET 
procedures are prohibited from caffeinated beverages in the 24 hours 
prior to testing.  N-13 is then injected into the patient’s bodies for about74 
Mbq. After the post injection, a 2 minutes scout scan was done in order 
to identify the correct position of the detectors over the heart. The time 
needed is about 4 minutes. After that, a transmission scan using Ge-68 
ring source was performed for 15 to 20 minutes followed by a baseline 
of N-13-ammonia.  Then, three minutes after the end of infusion of N-
13, data acquisition were acquired for 10 minutes.  From the procedures, 
it can be concluded that N-13-ammonia is avidly retained in hepatic 
tissue compared to other tracers like Ti-201 or Rb-82. Even without 
presence of CAD, it is observed that N-13-ammonia activity in 
posterolateral wall is reduced. Since, N-13 is retained in myocardial 
tissue in the form of glutamine, it explained the inhomogeneity of 
regional variation of its synthetase activity. 
 
11.2 CONCLUSION 
 
Nitrogen-13 is a very useful radionuclide in medical field as it involves 
in a lot of medical procedures especially in positron emission 
tomography (PET) for myocardial perfusion imaging, detecting coronary 
artery disease, quantify the myocardial blood flow and monitor the 
coronary flow of simplified PET. The N-13 is used as radio tracer in the 
body to deliver the radionuclide to the interest areas so that the tumor or 
any arterial failure can be detected and treated easily. It is also important 
to acknowledge the production of N-13 as it involves nuclear reaction. 
There are various methods to produce N-13, however the most efficient 
method need to be enhanced in order to produce a promising quality of 
radionuclide.  Further research need to be done by researchers and 
scientists to produce a better medical instrument involving radionuclide 
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to improve from what we have now to ensure a better quality nuclear 
medicine treatment to the society in the future. 
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CHAPTER 12 
 
BISMUTH-213 
 
Fatimah Mohd Rafieie 
 
12.0 INTRODUCTION 
 
Nuclear medicine is defining as the specialty of the practice of medicine 
dealing with the diagnostic, therapeutic and investigate use of 
radionuclides using radiation. Radioisotopes or radiopharmaceuticals are 
a crucial part of medical diagnostic procedures, introduced into the body. 
The study of dynamic processes can be performed in various parts of the 
body in combination with imaging devices that emits gamma rays. Small 
amounts of radiopharmaceuticals are used in nuclear medicine by 
injected into the bloodstream, inhaled or swallowed to identify the 
severity of or treat a variety of diseases, including cancers, heart disease, 
endocrine and other malformation within the body. 
 
Metastases, the spread of cancer cells to new areas of the body are the 
main cause of death compared to primary tumor in most fatal cancer 
cases. It is normally spread through the lymph system or bloodstream. 
The cancer may have spread to areas near the primary site called regional 
metastases or to parts of the body that are farther away called distant 
metastases. Large single tumors can often be stop by surgery but not for 
metastases, it can be very difficult to remove depending on size and 
amount. Epithelial cancers, such as prostate cancer, breast cancer and 
ovarian cancer are the examples of micrometastases. Micrometastases 
are very hard to treat because they cannot be detected by normal 
diagnosis methods, makes the survival rates low. As reported, the five-
year survival rate for people diagnosed with late-stage cancer that has 
metastasized (spread) to other areas of the body is only five percent. 
These carcinomas metastasize in an organ-specific pattern which most 
likely depends on mechanical factors such as how the cells are conveyed 
to the organ and the compatibility between the tumor cell and the new 
organ.   The majority of cancer related deaths cases in western 
industrialized countries are epithelial cancers. It is because of early 
metastasis that often occurred at the time of diagnosis. Even when cancer 
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spreads to a new location, the name of the cancer is still from area of 
body where it started. For example, a person with breast cancer that has 
spread to the bones is said to 
have breast cancer with bone metastases, otherwise it is called cancer of 
unknown primary origin if a cancer has spread widely throughout the 
body before it is discovered and it is unknown exactly where it started. 
 
A radiopharmaceutical is a chemical substance consists of radioactive 
atoms within its structure and is suitable for administration to humans for 
diagnosis or treatment of disease.  It is formulated in several chemical 
and physical forms to target radioactivity to particular parts of the body. 
The radioactive material traverses through the area being considered and 
emits energy in the form of gamma rays, allowing external detection and 
measurement which are detected by a special camera and a computer to 
create images of the inside of the body. The camera will focus on the area 
where the radioactive material also known as radiotracer is concerted to 
show the doctor what and where is the problem. Nuclear medicine can 
diagnose disease in earliest stages because they capable to spot molecular 
activity within the body.   The amount of radioactivity delivered to a 
patient in a nuclear medicine study is called dosage. The aim in 
diagnostic nuclear medicine is to apply the optimum dosage of 
radioactivity to obtain the information needed with the lowest radiation 
dose to the patient. This can be achieved by using short-lived 
radionuclides that decay rapidly, which does not make the radiation 
absorbed dose increase greatly when a larger amounts of radioactivity is 
applied. Radiopharmaceuticals with longer half-lives have desirable 
biochemical properties, which are why they are used in nuclear medicine. 
Tissue distribution studies are accomplished in animals to identify the 
organs that receive the highest radiation absorbed dose and estimate the 
radiation dose before radiopharmaceuticals are used in humans as they 
have radiation risk. The quantity of this dose estimate sets limits on the 
amount of radioactivity that can be safely applied to humans in diagnostic 
studies. Radiopharmaceuticals are conducted in very small amounts so 
that the chemical toxicity is not as great as compared to traditional 
pharmaceuticals, even the amount delivered in a standard dosage cannot 
produce a pharmacologic response. Before, single photons detected are 
used by a gamma camera that can observe various angles. The camera 
builds up an image from the points from which radiation is mitted. 
Therefore, the image is enhanced by a computer and viewed on a monitor 
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for indications of unusual conditions. Currently, single photon emission 
computerized tomography (SPECT) is the major scanning technology to 
diagnose and control a wide range of medical conditions. For safety 
purpose, procedures are needed to protect patients from excessive 
radiation exposure, personnel from the radioactive material that they 
handle and the general public from unnecessary exposure to radioactive 
environmental waste. However, the latest development, positron 
emission tomography (PET) shows more precise and advanced technique 
using isotopes produce in a cyclotron. 
 
In a chemical point of view, every organ in the body acts differently, so 
a number of chemicals which are absorbed by specific organs can be 
identified. For example, thyroid use iodine while brain consume 
quantities of glucose. This will assist radiopharmacists to link different 
types of radioisotopes to biologically active substances. 
 
Radiommunotherapy (RIT) is a type of targeted cancer therapy, allowing 
cytotoxic ionizing radiation to be delivered to tumor cells by connecting 
radionuclides to tumor-specific antibodies. RIT is particularly targeted to 
tumor cells, sparing healthy cells and tissues. RIT consists of two main 
components which are a tumor-specific antibody or antibody fragment 
and a radionuclide. The antibody fragment is injected into the patient to 
target and attach to the tumor cells in RIT. Unlabeled tumor specific 
antibodies can be labeled as a secondary standalone treatment and can 
have a tumor-preventing effect. However, this effect is not enough to 
remove all tumor cells in many cases. Thus, cytotoxic radionuclides are 
bind to the antibodies to increase the therapeutic effectiveness. The 
radiolabeled antibody conjugates in RIT can be handled in different ways 
depending on the nature of the disease. When the metastases primarily 
have a local spread, intracompartmental and intracavitary treatments are 
given and the targeting time is normally short in these cases. However, 
the targeting time can be long depending on the location of the tumor 
cells when RIT is given systemically and it will become obstacle in a 
systemic treatment, especially when using short-lived radionuclides. 
Different radionuclides are used based on their purposes in targeted 
therapy.  
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Suitable radionuclide is needed for every specific therapy. There are 
many important properties of the radionuclide such as physical half-life, 
decay chain, decay mode and chemical properties. Enough energy from 
the ionizing radiation has to be deposited in a tumor cell to acquire a 
sufficient therapeutic response. Linear energy transfer (LET) is used to 
classify the ionization density of a charged particle through matter. LET 
is measured in keV/µm, which means it states the energy deposited per 
path length unit of an emitted particle. Cell death as a result of irradiation 
is mainly caused by DNA damage, which can obtain either by the 
irradiation itself or by indirect effects such as radiation-induced free 
radicals. Different types of DNA damage can arise following irradiation, 
for example single strand breaks (SSBs), double strand breaks (DSBs) 
and multiple damaged sites (MDSs), which involve several types of 
scrapes in close proximity to each other. Normally, the DNA can be 
repaired easily from SSBs by repairing systems but for DSBs and MDSs, 
they are more complex and easily cause cell death. Low-LET radiation 
is less ionizing, so it is more vulnerable to result in SSBs, while the 
amount of DSBs increases with increasing LET. The probability that 
DSBs regain also reduces with increasing ionization density. 
 
12.1 APPLICATIONS 
 
There are only a few α emitters used for cancer therapy includes 
Bismuth-213 (213Bi). Bismuth is a metallic element with the atomic 
number of 83. This radionuclide has short half-life which is 45.6 minutes 
and decay with 100 % α emission. 98% of the 213Bi decays first with 
βemission to 213Po, which decays with α-emission to 209Pb with a half-
life of 4.2 µs. Another 2% decays with α-emission to 209Tl, which in turn 
decays with β-emission to 209Pb. 209Pb is a βemitter that decays with a 
half-life of 3.3 hours. 213Bi decays either directly or through α-emitting 
daughter nuclides with very short half-lives, based on their suitability for 
therapy. Although the half-life is very short, 213Bi is readily available as 
it can be produced by a generator. In their total decays, 213Bi emit gamma 
(γ) radiation which makes radioactivity determination with a gamma 
counter and imaging with a gamma camera practicable. 
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The 213Bi isotope is produced in the Institute for Transuranium Elements 
(ITU), the Commission’s Joint Research Centre in Karlsruhe. First test 
that is carried out at Memorial Sloan-Kettering Cancer Center in New 
York on leukemia patients showed very good results with no outstanding 
uptake of the isotope outside the target areas of bone marrow, liver and 
spleen. In order to reach the desired targets, the isotope is bind to a 
monoclonal antibody (HuM195).  One or two atoms of targeted 213Bi is 
enough to kill a cancer cell as it has high LET and the damage of normal 
tissue around the target cell is lower or absent as the path length is about 
60 cm. Alpha particle may kill cells by apoptotic mechanisms. 213Bi 
decay shows only low energy gamma rays, allowing its use without 
advanced shielding or protective equipment in the hospital.   213Bi is 
being researched for cancers such as leukemia, lymphomas and for 
micrometastatic carcinomas. 213Bi is most often assembled through a 225 
Ac-generator. Besides that, 213Bi can also be used for treatment in brain 
tumors. Secondary glioblastoma multiforme (GBM), the most common 
malignant brain tumor, continues from initially low-grade brain tumors 
and manifest mainly in younger patients. 
 
Primary GBMs spread quickly in more elderly patients without histologic 
evidence of precursor elements whereas secondary GBMs, which are 
around 9% of all grade IV tumors, progress from low-grade or anaplastic 
astrocytoma. GBM has been revealed to overexpress the neurokinin type 
1 (NK-1) receptor and substance P can be used as a ligand for targeted 
therapy. 213Bi allow the selective irradiation of tumor cells while sparing 
close to neuronal structures as it can deposit their high energy within a 
short range. Currently, GBM was treated by intracavitary injection of 1-
6 doses of 0.9-2.3 GBq 213Bi- DOTA-[Thi8,Met(O2)11]-substance P 
(213Bi-DOTASP) in 2-month intervals. 68Ga-DOTA-
[Thi8,Met(O2)11]-substance P (68Ga-DOTA-SP) was coinjected with 
the therapeutic doses to determine biodistribution using PET or CT. Post 
therapeutic scans were accomplished to evaluate tracer whole body 
biodistribution and expression of NK-1 receptor at the target area.  
Therapeutic response was monitored with MRI. 
 
Secondary GBM are more frequently occur in middle-aged individuals 
around the age of 45 years, while primary GBM manifest in older patients 
with a median age of 62 years. Secondary GBM are mostly found in 
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females while primary GBM mostly found in males. From log-rank tests, 
patients with primary GBM had a significantly shorter survival time 
compared to patients with secondary GBM.  The data from a study on 
targeted alpha therapy of brain tumors led by the Medical University of 
Warsaw in cooperation with the JRC indicate that the mean of survival 
time in untreated patients with secondary GBM are 7.8 months while for 
patients after standard therapy including surgery and radiotherapy are 27 
months. These outcomes show that targeted alpha therapy may progress 
for therapy of secondary GBM.  213Bi radionuclide generators can be 
safely handled if the official procedures and standard equipment which 
available in nuclear medicine departments are followed. However, for a 
widespread clinical application, the supply of 225Ac as mother nuclide 
for 225Ac/213Bi generators must be significantly increased beyond 
existing limited levels. Accelerator-driven processes that allow its 
production on a large scale have been developed and need to be 
implemented to overcome these supply limitations.  In conclusion, 
treatment of secondary GBM using 213Bi-DOTA-SP analogue is safe 
and well tolerated.  
 
12.2 CONCLUSION 
 
In conclusion, Bismuth-213 is one of the radionuclides that can be used 
for treatment in nuclear medicine. It decays only low energy which can 
be used in hospital. Besides that, therapy with alpha emitters can 
overcome resistance to therapy with conventional drugs and also with 
beta emitters and can offer a valuable additional treatment option to 
patient that have failed established treatment. Bismuth-213 are highly 
cytotoxic radionuclides, so it can provide remarkable benefit to cancer 
patient. 
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CHAPTER 13 
 
 IODINE-123 
 
Amirul Irfin Ghazali 
 
13.0 INTRODUCTION 
 
Radiopharmaceutical is a chemical substance that contains radioactive 
atoms within its structure and is suitable for administration to human 
diagnosis or treatment in disease. It is formulated in variation of chemical 
and physical shape to target radioactivity to particular parts of the body. 
Energy that being release by the radionuclides in forms of gamma ray are 
being used for detection while beta particles that are being release is use 
for treatment of a disease. 
 
In nuclear medicine, radiopharmaceuticals is used for three different 
procedures. Imaging procedures by using radiopharmaceuticals is to 
provide diagnostic information based on the pattern of radioactivity 
distribution in the body. The procedure is divided to two which is 
dynamic studies and static studies. Dynamic studies are the study of a 
radioactivity when its entering and leaving the body. It will provide 
functional information of the organ by measuring the rate of the 
radiopharmaceutical accumulate and leaving the body. Static imaging are 
study of information of an organ after radiopharmaceuticals is 
accumulating in the organ of interest.  
 
In vivo function is involving the organ function based on the absorption, 
dilution, concentration or excretion of radioactivity after taking a 
radiopharmaceuticals. The examples are radioactive iodine uptake to 
analyze the thyroid gland function. Therapeutic procedure is a procedure 
that use to be curative or palliative that destroy diseased tissue by the 
absorption of beta radiation. 
 
 
 
 
 
 67 
 
Applications of Radiopharmaceutical in Nuclear Medicine
   ISBN 978-967-2306-01-6
2019 
Iodine is a chemical element with an atomic number of 53. It is a halogen 
which is on the heavier side. It is the heaviest one from the halogen group. 
It has 37 known isotopes but only one of it is exist naturally. Iodine is 
important for in human health especially the synthesis of thyroid 
hormones in the human body. 
 
Iodine-123 is one of the isotopes of iodine that used in 
radiopharmaceuticals. It decays by electron capture to produce telurrium-
123, emits gamma ray in the process and has a half-life of thirteen hours. 
In nuclear medicine, it is primarily used for imaging which include 
Single Photon Emission Computed Tomography (SPECT) and X-ray 
computed tomography (CT) scan. Iodine-123 is produced by using 
cyclotron. In SPECT, Iodine-123 is produced by bombarding a tellurium 
target with proton. Iodine also produced by nuclear reaction .Inert 
Xenon-123 gaseous and chemically separated from the irradiated target 
and then decayed to Iodine 123. 
 
13.1 APPLICATIONS 
 
In nuclear medicine, Iodine-123 is use for pheochromocytoma, carcinoid 
tumours, no secreting paragangliomas, neuroblastoma which is given by 
iobenguane injection. Mainly, Iodine is famously use for thyroid gland 
imaging and thyroid metastases. The iodine is consuming in form of 
sodium iodide capsule and solution.  
 
Thyroid gland is made up of huge number of follicles and each of them 
is lined with epithelial cells that are filled with colloid. Colloid is made 
up of thyroglobulin that are the base for production and storage of thyroid 
hormones. Iodine that are ingested in the body is taken up by blood and 
oxidise and reacts with tyrosine residues in thyroglobulin to form thyroid 
hormone that are stored in the colloid. Thyroid gland is controlled by the 
hypothalamic-pituitary axis through a feedback mechanism. As the 
thyroid hormone levels decrease, hypothalamus secrete thyrotropin-
releasing factor that will induce the release of Thyroid Stimulating 
Hormone (TSH) from the anterior pituitary that will stimulate thyroid 
gland to produce more hormone. When hormone is excess, negative 
feedback is induce by the thyroid hormone that causes TSH levels to and 
the production of thyroid hormone is reduce. 
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Hyperthyroidism occurs when the thyroid gland enlarge to 2 to 3 times 
of the original size and secretes excessive amount of thyroid hormone 
which is up to 5 to 15 from normal. The suppressive feedback it had on 
the anterior pituitary gland making the TSH levels to be below normal or 
near zero. One of the causes of hyperthyroidism is Grave’s disease. The 
disease is caused by thyroid-stimulating immunoglobulins that stimulate 
TSH receptors on the thyroid cells. Toxic nodular goitre cause 
hyperthyroidism by enlarging the gland with multiple hyper functioning 
nodules which is Plummer’s disease or just one nodule that is hyper 
functioning adenoma. The tissue will show an accumulation increase of 
radioiodine when scanned. 
 
Thyroiditis is caused by the inflammation of the thyroid gland. At first, 
a hyperthyroid phase is caused by inflammation-induce release of thyroid 
hormone that are stored in the gland which develop into hyperthyroidism. 
Chronic thyroiditis is an autoimmune inflammatory disease. It is a result 
when thyroid parenchymal cells are increasingly replaced by 
lymphocytes and plasma cell and by fibrosis eventually which will 
eventually cause hypothyroidism. 
 
Nodule that form in thyroid are something usual but is must be evaluated 
just in case it is cancer. Nodule that are accumulating radioiodine are a 
functional nodule. An autonomous nodule is not controlled by TSH. An 
autonomous nodule can be very large and provided thyroid for the 
function of the whole body and also can be to big that produce excessive 
hormone that may develop into thyrotoxic or hyperthyroid. The nodule 
can supress the release of TSH from the pituitary and which will result 
in suppression of the normal thyroid tissue. 
 
Iodine 123 are available in capsule form with a 100 and 200 μCi for 
diagnostic studies. The capsule is given to a patient to determine the 
thyroid function. For Radioactive iodine uptake test (RAIU), capsule that 
given to the patient are counted as the standard count. The patient’s 
thyroid gland count are compared to the standard count. Each capsule 
given is setting the standard.     The radioiodine is absorb rapidly by the 
gastrointestinal at a rate of 5% per minute. The absorption is complete 
within 1 to 2 hours depending with the present of food. The radioiodine 
is widely distributed in the body and excreted most of it within 24 hours. 
The residue is localized at the thyroid gland. Radioiodine plays an 
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important role in the thyroid gland. The amount of the radiation dose to 
the gland and other organ and the total body are dependent on the 
administered radionuclide and gland uptake. For Iodine-123, the 
radiation dose absorb by the thyroid gland is 13 Rad compare to the 
whole body, 0.029 Rad. Iodine-123 administered activity is 200-400 μCi. 
It is taken orally and take time to image after dose is 24 hours. The 
thyroid dose administered is 0.013 μCi. 
 
13.2 CONCLUSIONS 
For iodine-123, there are no safety consideration after intake because the 
radioiodine have a short half-life. The radioiodine are excreted through 
the urine. After urinating, the toilet have to be flush twice and hands have 
to be wash thoroughly. A pregnant and lactating woman should inform 
the operator of their condition before been administered a radiotracer. 
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CHAPTER 14  
 IODINE-125 
Siti Khairunnisa Mustafha 
 
14.0 INTRODUCTION 
Iodine-125 is an isotope of the element iodine and is the second longest-
lived radioisotope of iodine, after Iodine-129. Its half-life is 59.49 days 
and it decays by electron capture to an excited state of tellurium-125. The 
atomic number of 125I is 125 while its proton number is 72. Iodine-125 is 
created by the electron capture decay of 124Xe.  
 
         124Xe (n,γ)→ 125mXe(57s)→125I (59,4 d)                         (14.1)                                       
         124Xe (n,γ)→ 125gXe(19,9h)→125I (59,4 d)                       (14.2)                           
Iodine-125 goes through positron emission, a type of radioactive decay 
in which one of the protons in the nucleus becomes a neutron. This causes 
the changing proton to release a positron, which is a positively charged 
beta particle. Iodine-125 is produced in only one place in the United 
States, at the McClellan Nuclear Radiation Center on the campus of the 
University of California, Davis (Liu).  
 
Iodine-125 is a radioisotope of iodine which has uses in biological 
assays, nuclear medicine imaging and in radiation therapy as 
brachytherapy to treat a number of conditions, including prostate cancer, 
uveal melanomas, and brain tumors. 125I is a preferred isotope for tagging 
antibodies in radioimmunoassay and other gamma-counting procedures 
involving proteins outside the body. 
 
Brachytherapy is a type of radiation used to treat cancer, involving the 
placement of a radioactive material, either temporarily or permanently, 
directly inside the body. Brachytherapy delivers the radioactive dose 
directly within or adjacent to the tumor from the outside. The principle 
of brachytherapy is to deliver low-intensity radiation over an extended 
period to a relatively small volume of tissue. The low intensity isotopes 
are placed directly into a tissue or cavity depositing radiation only a short 
distance, covering the tumor area but sparing surrounding normal tissue. 
Brachytherapy has been most widely used in the treatment of cervical, 
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prostate, breast and skin cancers.  
 
In brachytherapy, the radiation dose is placed in the sealed sources before 
applied to the tumor. They are enclosed in a protective capsule or wire 
which allows the ionizing radiation to escape to treat and kill surrounding 
tissue, but prevents the charge of radioisotope from moving or dissolving 
in the body fluids. Sources can be tubes, needles, wire, pellets or seeds. 
Brachytherapy sources are usually encapsulated and the capsule serves 
several purposes: 
• Containing the radioactivity 
• Providing source rigidity 
• Absorbing any alpha, and for photon emitting sources, beta 
radiation through the source decay. 
 
14.1 APPLICATIONS 
14.1.1 Treatment For Prostate Cancer 
Prostate cancer is the commonest malignancy, and second biggest 
contributor to cancer mortality among men. It is one of the very common 
diseases of ageing men which is less common before age 50. Prostate 
cancer is a major health concern for American men while in Asia, Africa 
and Latin America, prostate cancer is rare. It has also been noticed 
recently, that incidences of prostate cancers are on increase specially in 
many developing countries mainly because of long survival time due to 
better health care facilities available now-a-days and also due to changes 
in lifestyles of population of these countries. 
 
For disease that is likely confined to the prostate and the immediate 
surrounding area, surgery, external beam radiation (EBRT) and seed 
implantation are the primary treatment options. In recent years, seed 
implantation has become more popular as a treatment option as it is 
simpler, less traumatic and the duration of relief is comparable. It has 
been estimated that up to 50% of patients with early stage prostate cancer 
are now receiving ultra sound guided seed implantation.  
 
The treatment for prostate cancer that uses Iodine-125 is called 
brachytherapy. In this treatment, small seeds of Iodine-125 about the size 
of a grain of rice each, are place in the prostate grain. The number of 
seeds used varies from 70 to 150 seeds depending on the size of the gland. 
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Before the procedure begins, doctor conduct an ultrasound to determine 
the size of the prostate gland as well as the best places to put the seeds. 
The seeds are placed in the prostate gland by sticking needles with the 
seeds on their tips into the skin in between the rectum and the scrotum. 
Once the needles have penetrated the gland they are guided to 
predetermined destination in the prostate. The procedures takes about an 
hour, but patients should avoid strenuous activity or heavy lifting for a 
few days after they received treatment. If they are feeling well after 
seventy-two hours they can return to a normal level of activity.  
 
Before the procedure, patient will be given medicine so that it won’t feel 
pain. A sedative is given to make the patient drowsy and numbing area 
between the anus and rectum. While using anesthesia, patient will be 
drowsy but awake and pain-free. After receiving anesthesia, the doctor 
placed an ultrasound probe into the rectum to view the area. The probe is 
like a camera connected to a video monitor in the room. The doctor uses 
ultrasound or a CT scan to plan and then places the seed. 
 
Another option to treat prostate cancer is very similar procedure using 
the Paladium-103. The costs of the two treatments are relatively even as 
are the side effects. Side effects may include burning during urination 
urgency to urinate, mild bleeding during urination and frequent urination. 
Another complication can be the expulsion of one of the seeds through 
urination. Because of this, patient is asked to filter their urine for one 
week after receiving treatment. 
 
Patients are allowed to be around people in general with two exceptions 
which are small children and pregnant women. Iodine-125 emits very 
low levels of radiation that are mostly absorbed by the gland itself and 
the radiation cannot travel more than a few feet in through air, but the 
two groups previously mentioned should try to maintain a distance of six 
feet from the patient for the first month following an implant. This may 
cause problems for patients in terms of the level of contact they are 
allowed to have with their families if they have small children. 
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14.1.2 Treatment for Brain Tumor 
 
Iodine-125 brachytherapy has been applied to brain tumours since 1979. 
The implantation of radioactive material into tumours was proposed by 
Pierre Curie in 1901. In 1951, Friedlander and Orr prepared iodine-125 
by alpha bombardment of natural antimony. Nowadays, temporary 
implantation of iodine-125 seeds is preferred for interstitial 
brachytherapy in brain tumors. Despite favourable physical and 
biological characteristics of brachytherapy and well established 
implantation techniques, so far brachytherapy treatment of brain tumors 
has been performed in only a few centres worldwide.  
 
Iodine-125 emits gamma-rays with a very low average photon energy of 
28.5 keV, has a specific gamma ray constant of 1.32-1.45R· cm2 /mCi·h, 
a long half-life of 59.4-60.2 days, a half-value tissue thickness of 2 cm 
and for lead of 0.025 mm, which enables easy shielding. Iodine-125 
implants generate a typically extreme dose inhomogeneity within target 
volumes that ranges from highly necrotizing doses surrounding the seeds 
to the ultimate form of fractionation at the periphery of target volumes. 
Iodine-125 brachytherapy is a valuable treatment option for patients with 
non-resectable, small, and circumscribed untreated tumors in any 
location of the brain. 
 
There are two forms of iodine-125 brachytherapy techniques which is 
temporary and permanent. For temporary implant, CT or MRI is used for 
tumor localization. Neurosurgeon placed the catheter precutaneously and 
parallel to each other at the calculated positions. After 24 hour 
implantation, CECT for analysis of the catheter configuration and 
treatment planning. After 6 days and delivery 50GY to tumor and its 
margin, the catheters are dislodged.  
 
In permanent implant, the source used is low activity of iodine-125 seeds. 
Source are placed along the walls of the resection cavity at 1.5cm to 
1.0cm intervals. Also, removal of the catheters can be done without 
anesthesia. During the tumor resection, the balloon portion of the 
GliaSite catheter is placed within the resection cavity. The other end of 
the catheter serves as the injection port and is fixed on top of the skull 
and concealed underneath the skin. 
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14.1.3 Treatment in Hyperthyroidism 
 
Iodine-125 is conventionally used in the treatment of hyperthyroidism. 
Hyperthyroidism (overactive thyroid) is a condition in which thyroid 
gland produces too much of the hormone thyroxine because the cell in 
the gland being over stimulated. Since the thyroid is the only organ in the 
body that uses the iodine, treatment for hyperthyroidism involves taking 
a pill of iodine-125 cased in the titanium. Compared to the Iodine-131, 
the radiation from Iodine-125 is largely of low energy electron with a 
shorter range. So, its radiobiological effects will therefore be 
concentrated on the apex of the thyroid cell adjacent to the colloid where 
iodine is stored.  
 
The iodine-125 goes to the thyroid and stays there long enough to begin 
radiating in the gland and slow down the production of the hormones. 
Treatment usually lasts around three months but can take up to six 
months in rare cases. There are no side effects associated with radioactive 
iodine treatment for hyperthyroidism. An alternative to this treatment is 
antithyroid medicines, which are recommended for pregnant and nursing 
women, as well as people with mild hyperthyroidism, but for most 
people, radiation treatment is the best option. 
 
14.1.4 Radioimmunoassay 
 
Radioimmunoassay (RIA) is an in vitro assay that measures the presence 
of an antigen with very high sensitivity. This technique was first 
developed by two endocrinologists, S. A. Berson and Rosalyn Yalow, to 
determine levels of insulin-anti-insulin complexes in diabetics. 
Radioimmunoassay utilize a radioactive label which emits radiation that 
can be measured with a gamma or beta counter . 
 
The principle of RIA involves competitive binding of radiolabeled 
antigen and unlabeled antigen to a high-affinity antibody. The labeled 
antigen is mixed with antibody at a concentration that saturate the 
antigen-binding sites of the antibody. Then test samples of unlabeled 
antigen of unknown concentration are added in progressively larger 
amounts. The antibody does not distinguish labeled from unlabeled 
antigen, so the two kinds of antigen compete for available binding sites 
on the antibody. As the concentration of unlabeled antigen increases, 
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more labeled antigen will be displaced from the binding sites. The 
decrease in the amount of radiolabeled antigen bound to specific 
antibody in the presence of the test sample is measured in order to 
determine the amount of antigen present in the test sample. 
 
Iodine-125 is one of the radioisotopes used in radioimmunoassay(RIA). 
The two scientists, Rosalyn Yalow and Solomon Berson had been 
tracking the insulin that went into the bodies of diabetics using an atom 
of iodine-125. If they detected the insulin in the urine of the patient, they 
knew that the body had absorbed the insulin. They soon realized that they 
could do a similar thing with hormones and other substances in the body. 
This is where the discover RIA. They found that if they tagged a known 
quantity of hormone and measured the radioactivity of the tagged 
hormones. Then, they mix into a solution with naturally occurring 
antibodies to form hormone-antibody pair. These pairs are then added to 
some of the patient’s blood with an unknown quantity of the same 
hormones. 
 
Since the antibodies prefer the non-radioactive ones, they gradually drift 
over to the non-radioactive hormones. A scientist then measures the 
radioactivity of the solution and the difference in radioactivity between 
that of the tagged hormones and that of the solution is the quantity of the 
hormones that was unknown. This can use to detect an excess of antigens 
associated with cancer is the blood stream and can be used to detect 
almost any type of cancer. 
 
14.1.5 Treatment in Breast cancer 
 
A relatively new technique is the implantation of iodine-labeled titanium 
seeds (I-125 seed). Some studies have already reported successful use of 
I-125 seed implantation in primary non-palpable breast tumors. The use 
of one or more I-125 seeds provides optimal per-operative three 
dimensional orientation, especially in technical more challenging 
procedures like for residual multifocal tumors. In comparative studies on 
different localization techniques of non-palpable breast tumors, the I-125 
seed localization technique has been reported to be preferred by surgeons 
because of its easy use with reduced operative times and better 
preoperative navigation . 
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A titanium seed containing iodine-125 was injected into the tumor bed 
using US guidance. The seed was loaded into a gauge needle. The tip was 
sealed with sterile bone wax to prevent the loss of the seed before 
introduction into the breast. The seed is then deployed into the breast by 
using a technique similar to traditional wire localization. Seeds can be 
placed within or adjacent to a single lesion. After seed implantation, a 
confirming mammography was carried out. Once in the operating room, 
the surgeon localizes the seed using a gamma detection probe. The 
surgeon must handle the specimen with care during excision to avoid 
seed extrusion. A protective sock is placed within the suction canister to 
trap a seed if it is inadvertently extruded and suctioned during surgical 
excision. 
 
The pathologist accompanies the specimen to the gross specimen 
laboratory and oversees removal of the seed from the specimen. After the 
specimen is inked, a gloved gamma detection probe is used to ensure the 
presence of radioactivity before cut-down of the specimen for seed 
extraction. The radioactive seed is then carefully retrieved from the 
specimen by using a hemostat.  Once obtained, the seed is placed in a 
lead envelope and collected in a secure location for storage. Iodine-125 
(125I) radioactive seed localization (RSL) is a safe, effective, and 
increasingly used procedure for the preoperative localization of 
nonpalpable breast lesions.  
 
14.2 CONCLUSIONS 
Iodine-125 is a medical isotope that is not found in nature. It has a half-
life of about 60 days. Iodine-125 can be converted into x-rays and emits 
gamma ray. Also, this has two biological uses in medicine imaging and 
radiation therapy. It is mostly used in nuclear medicine for treating 
various cancers such as brain tumor, prostate cancer and breast cancer in 
brachytherapy technique. In medical applications, the internal conversion 
and Auger electrons cause little damage outside the cell which contains 
the isotope atom. The X-rays and gamma rays are of low enough energy 
to deliver a higher radiation dose selectively to nearby tissues, in 
"permanent" brachytherapy where the isotope capsules are left in place. 
Iodine-125 radioactive seed tissue implantation is a feasible, effective, 
and safe treatment method. Also, Iodine-125 seed implantation provide 
a safe and effective method to relieve pain, control local tumor growth.  
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CHAPTER 15 
 
IODINE-131 
 
Siti Sarah Malike 
 
15.0 INTRODUCTION 
 
Nuclear medicine is the introduction from diagnosis to therapy diagnostic 
by imaging is an essential tool in the detection of many diseases such as 
cancer in the nuclear medicine. Department a radiopharmaceutical is 
injected to the patient radiopharmaceutical distributes itself in the whole 
body and concentrates in the diseases areas. It is taken up by the lesion 
and any residual is naturally eliminated. The patient is then transferred 
into the camera. Radioactivity allows providing an image.  
 
Radioactive iodine-131 is produced artificially in nuclear reactors. This 
mean it is man-made because it does not occur naturally. I-131 is 
produced by nuclear fission. This is the splitting of a large atom into two 
or more smaller ones with the release of and energy by nuclear reaction. 
The nucleus of natural isotope tellurium is bombarded with neutrons in a 
nuclear reactor. This results in an increased number of neutrons in the 
nucleus precisely. This becomes Tellurium 131 (Te-131) with the one 
added neutron which decays to form I-131 with one added neutron which 
decays further to form iron 131 and as this decays it emits gamma and 
beta radiation.  
 
The radioactive iodine concentrates in the thyroid going and emits both 
this radiation  which kills the abnormal cells. This is because the cancer 
cells are more susceptible to radiation than normal cells. Meaning they 
attract these beta and gamma radiations killing the cells. Iodine is created 
by nuclear decay by beta emission and gamma emission. It has a half-life 
8.0197 days. It undergoes nuclear fission and has daughter nuclei of 
xenon and parent nuclei of iodine. Iodine is an artificially produced 
fission by-product. It is a result from nuclear weapons above ground 
nuclear testing and form waste streams of nuclear power plants iodine-
131 is used to treat some diseases of the thyroid gland. This includes to 
treatment for hyperthyroidism caused by Graves disease or nodule in the 
thyroid gland. It is administered through a capsule as it is a radioactive 
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isotope. It emits beta radiation that kills parts of the thyroid gland. 
 
15.1 APPLICATIONS 
Iodine-131 therapy is used for patients that have an overactive thyroid 
and papillary thyroid cancer. Overactive thyroid is when one thyroid 
gland produces excess thyroid Foreman iodine-131 therapies helps kill 
parts of the thyroid gland so it can function normally.  Once the polar 
airy fiber cancer is detected, the thyroid gland must be removed after 
removing the gland patients may be prescribed Iodine-131 to ensure the 
tissue is completely destroyed. Success rate of iodine-131 treatment 
varies between 75% to 100%.   
 
Radioactive iodine-131 therapy is beneficial from an economic and 
social perspective iodine-131. Treatment is inexpensive for average 
income producer treatment. The successful rate extremely high and this 
is beneficial for people who are affected by overactive thyroid and 
papillary thyroid cancer. This treatment helps reduce their symptoms and 
helps them live a normal life.  Iodine-131 also has disadvantages if 
accidently released into the environment. It can cause great impact once 
release a purple vapour from that enters the food chain affecting 
vegetation and water quality economically. It is very bad if iodine-131 is 
released into the environment. It becomes very expensive as ecosystems 
must be monitored and iodine-131 has to be eliminated from the food 
chain. Radioactive iodine has been used successfully as a therapy for 
thyroid disease for more than 50 years. Uses of iodine -131 are one of the 
most used radioactive isotopes in the Medicine Industry today. Example 
of uses such as diagnostic tool for liver and kidney function 
abnormalities, smaller doses of I-131 are used to study and treat thyroid 
abnormalities like cancer cells, and larger doses are used as radiation to 
treat tumours in the thyroid. 
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15.1.1 Benefits  
 
• If successful, there will be reduced chances of cancer 
spreading and functioning of the Thyroid will return to normal. 
• Effective Treatment – only absorbed by the thyroid cells. This 
because the thyroid cells are the only cells in the body that can 
absorb iodine. This allows the therapy to work effectively on 
the target cells and cause no damage to the rest of the body. 
• The treatment process can be personalised to the patient 
reducing side effects – people having iodine therapy will have 
their dosages calculated carefully in relation to their body 
weight and levels of cancerous cells.  
 
15.1.2 Limitations  
• Pregnant women cannot receive iodine treatment – this is 
because the radiation can have an effect on the unborn baby by 
harming the foetus.   
• Brief changes to lifestyle of the patient – usually occurs for 
seven days after any treatment iodine 131 (restricts patients 
from coming in close contact with other people.  
• Iodine can be transferred in saliva and urine so toilet precautions 
do also occur like flushing twice in cleaning the toilet seat 
Iodine-131 used therapeutically and it is used for the treatment of 
overactive thyroid which is a condition called hyperthyroidism. It can 
cause Graves’ disease which is when the entire fibroid gland is 
overactive. The iodine-131 is absorbed into the gastrointestinal tract and 
then starts to eradicate the gland cells. Beta radiation kills the thyroid 
cells that are overactive but only travels a small distance usually not 
exiting body.   
 
The gamma radiation however does travel several metres away from the 
patient and traces the progress three days later. This is why when under 
this treatment the patients are advised to not make much physical contact 
with other human. Beta radiation is made up of high-energy electrons 
admitted from the nucleus and is penetrated by thick aluminium. A 
gamma radiation is a short of wavelength of electromagnetic radiation 
and can be penetrated by cichlid. There are many benefits from using this 
radioisotope. 
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The beneficial as it completely destroys any harmful cancerous thyroid 
tissue. It also makes our thyroid function habitually which is important 
as it controls our metabolism. This radioisotope also increases the level 
of sensitivity when detecting any diseases and has minimal side effects 
as well as iodine-131 has a half-life of roughly 8.02 days. This means 
that patients who are living far away from the treatment have time to 
reach the facility before this radioisotope decayed into xenon-131.   
 
15.2 CONCLUSIONS 
 
The advantages worth using iodine-131 for an overactive thyroid are:  
• Therapy should make the thyroid to start functioning normally   
• The thyroid controls the body’s metabolism, it should give 
most of the patients a better quality of life. 
• The treatment completely destroys any harmful cancerous 
cells. 
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CHAPTER 16 
 
TECHNETIUM-99m 
 
Nurin Saqinah Jasrin 
 
16.0 INTRODUCTION 
 
Technetium-99m is one of the radiopharmaceuticals that used in nuclear 
medicine treatment. Techenetium-99m emits gamma ray energy about 
140 keV which is convenient for detection. The letter of "m" represent 
that Technetium-99m is a metastable nuclear isomer. Metastable nuclear 
isomer means that the decay product whose nucleus remains in an excited 
state much longer than the typical one. This is because normally a gamma 
ray is emitted at almost exactly the same time as an alpha or beta particle.  
However, the Technetium-99m are delayed between its production and 
emits its gamma ray. The basic properties of this substance included their 
atomic weight which are 99 and 43 as the atomic number. Technetium-
99 is present in soluble with Nitric Acid, Aqua Regia and concentrated 
of Sulfuric Acid nitric acid meanwhile this substance is insoluble in 
Hydrochloric acid. 
 
Techentium-99m are produced when Molybdenum-98 (98Mo) 
bombarding with neutrons. As the results,99Mo with the decaying for 66 
hours of half-life to the metastable state of (Technetium). The production 
of Technetium-99m are applicable in nuclear medicine due to the short 
half-life about six hours and safe to used. For nuclear medicine purposes, 
the 99mTc is used in the form of pertechnetate, TcO4.The short half-life of 
Technetium-99m are impossible to store in long period. The Technetium-
99m generator are produced to allows the production of Techenetium-
99m when required. These generators are transport to the hospital when 
the ready produced Mo99 placed into this generator. The saline solution 
is used to milked the molybdenum which like to bond with aluminium 
oxide. The Technetium-99m drawn away with the saline and ready used 
for tested. The Technetium-99m are coming out together with saline 
solution because it not bonded with alumina unlike Molybdenum. The 
saline solution is used due to the suitability injected in our body. 
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The process started by placed the sample of molybdenum and aluminium 
oxide placed at the centre of Technetium Generator device. After that, 
the saline solution is injected through one of the tubes at the top of the 
device and flows into the shielded container through the other tube. 
Finally, the Technetium-99 can be taken after the solution pass through 
the sample in the generator. This process of isolated a single chemical 
compound from mixture are following a method that name as column 
chromatography. There is some ideal characteristic which allow 
Technetium-99m able to be used in nuclear medicine. Techenetium-99m 
has a very short half-life which is about 6 hours that manage to examine 
the metabolic process. The data can collect rapidly due to the short half -
life of this nuclear isomer. In addition, it allows to reduce the radiation 
dose of the patient. Even this nuclear isomer only emits low gamma 
radiation, it sufficient to detectable by gamma camera. As a result, the 
severity tissue damage could be reduced, and it can eliminate from our 
body in short time period. The decay process of Techenetium99m emits 
low beta emission and has short time half -life so that, the radiation 
exposure to the patient can be reduced.  
 
Other than that, the reaction of Technetium-99m can be react depend on 
it situation that suitable for organ examine such as liver, lungs, bones and 
thyroid by forming a compound which leads concentration to it organ. 
Techenetium-99m triggers the biologically chemical to be produce in 
wide range due to being able to vary the number of oxidation states. So 
that, it can be corporate with the biological molecule to react with the 
organ interest. Both characteristic which is short-half life and has a 
versatile chemistry in the sense it can be attached to a variety of chemical 
to image depends on organ interest leads to fast elimination dose from 
body after imaging process. 
 
16.1 APPLICATIONS 
 
Technetium-99m are extensively used in medical application. The higher 
energy of gamma ray about 140keV are appropriate to be used in 
diagnosis as radioactive tracer. The techenetium-99m are not only used 
for skeleton image but also able to apply for brain, thyroid, lungs, liver, 
spleen, gall bladder and bone marrow. Technetium-99m are a 
radioisotope which emitting gamma rays. This allows Technetium-99m 
to be used for single photon emission computed tomography (SPECT). 
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SPECT are a nuclear imaging technique which used gamma to be detect 
by the gamma camera. When the radioisotope injected in the patient body 
and the concentrated will attached to the organ interest and give a signal 
for gamma camera detect it. The gamma camera need to be rotate every 
three to six degree of patient body until reach 360o for recording the 
detectable data. This projection takes about 15-20 minutes to finished. 
 
Technetium-99m also have been used widely in bone and brain scans. 
Bone scans can be used directly to heal the skeletal injury and some cases 
are allowing the Techenetium-99m to react with tumour of the bones. It 
also able to detect strokes by brain scanning. The properties of 
Technetium-99m radioisotope are able to identify the lymph nodes drain 
cancer such as breast cancer. The radioisotope will be used together with 
antimony sulphide colloid as radioactive maker in our body to detect the 
abnormal activity of lymph nodes. This radioactive maker is injected by 
shielding syringe to lymph node drain area and the area spotted with 
abnormal activity as the area of cancer growth.  
 
Next, the immunoscintigraphy are a process to detect hard-to-find 
cancers by injected the Technetium-99m into monoclonal antibody. 
Monoclonal antibody is one of the immune system proteins that capable 
to binding with cancer cells. Medical equipment will be detected the 
gamma ray that emits by technetium-99m and diagnose that the higher 
concentration indicates the location of tumours. It usually related with 
intestine organ treatment.  
 
Other than that, Technetium-99m are incorporate with tin compound to 
detect gastrointestinal bleeding sites. The detection occurs by bind them 
with red blood cells and maps the circulatory system disorders. 
Technetium-99m is what is known as a metastable state nuclide. It has 
more energy in the atomic nucleus than the normal state. So that, safety 
precaution need to be concern in handling Technetium-99m. 
Technetium-99m will present a risk if it gains entry to the body either by 
inhaled, ingested or injected. It risks varies according to the chemical 
form. Basic handling precaution can be include wearing personal 
protective equipment such as suitable glove, mask and disposable lab 
coat as the second protection. A lead apron can shield a small amount of 
exposure but still able to reduce about 50% of radiation level. So, the lead 
apron need to be wear unless the clothe worn able to protect and against 
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contamination.  
 
The area of handling Technetium need to be design properly and the 
container need to be label clearly. The storage of Tc-99m need to be 
shield by high density material. The storage temperature need to maintain 
in room temperature condition. It also important to ensure the Tc-99m 
keep in lead and away from heat and flammable area. A shielding syringe 
(Figure 5.0) need to be used when injected the dose to the patient. It to 
reduce the radiation exposure to the medical physicist. However, always 
beware of any leakage syringe and limit the exposure time when handling 
the radioisotope. Waste management of the Tc-99m are substantial to 
ensure the waste are not reach exceed limit of safe exposure to the 
environment and individual. There are some advantages of using 
Technetium-99m as radioactive maker in nuclear medicine. Firstly, it can 
be examined metabolic process based on organ interest and not give harm 
effect to human body. Moreover, the short half-life make it quickly 
eliminates from our body and then the damage cell tissue could be 
reduced. In addition, the reaction to diagnosis are quite fast compared 
others radioisotope. The pure gamma rays emit from Tc-99m are 
detectable even in low energy as well can short the time exposure to the 
patient body. This is due to common injection for a Technetium-99m 
diagnostic test is about 250 MBq which only 0.05 Sv radiation dose. So 
that means the dose are far below the demarcation for radiation and not 
consider as poisonous radiation. Next, Tc-99m are able to investigate 
hard-find cancer. The versatile combination compound makes Tc-99m 
able to react with suitable organ interest in our body. Finally, it can be 
diagnosis widely for many organs like brain, thyroid gland, kidney and 
muscle heart. 
 
However, there are some limitation and problem in using Technetium-
99m. It need high cost to produce the isotope and required nuclear reactor 
to produce Mo-98 before generated it by Technetium-99m generator. 
Radioactive waste management also need to be concern to protect others 
from radiation exposure. If tissue damage occurs, it may lead sickness 
and death if continuous high radiation expose. In long time period after 
the treatment a genetic damage that cause abnormal offspring and 
uncontrol cell growth (cancer) could be occurs. In addition, the short-
half-life limiting the procedure performance of drainage the lymphatic 
system and risks of leakage are higher. The visualization only can be 
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illustrated by gamma camera and some of cases state that deep lymphatic 
cannot be visualized.  
 
 
16.2 CONCLUSION 
 
As conclusion, Technetium-99m are one of the radioactive transition 
metals that used as radioactive maker agent. It able to act as preparation, 
cellular absorption, imaging, and elimination of agent due it short half-
life. Technetium-99m are widely used for diagnosis many organs 
included brain, thyroid, heart muscle and also skeleton injury. It able to 
reduce the radiation dose exposure for patient which lead less tissue 
damage. The production of Technetium-99m by its generators 
contributed extensively usage in nuclear medicine. 
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